Edgar Filing: MILLENNIUM CHEMICALS INC

Three Months Ended
March 31,

(Millions)

Operating income

Amended 10-Q

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

(AMENDMENT NO. 4)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2004

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 1-12091

MILLENNIUM CHEMICALS INC.

(Exact name of registrant as specified in its charter)

Delaware

22-3436215

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

1221 McKinney Street, Suite 700

Houston, Texas 77010

(Address of principal executive offices)

713-652-7200

(Registrant’s telephone number, including area code)

(Information regarding address and telephone number reflects changes resulting from

Lyondell Chemical Company’s November 30, 2004 acquisition of the registrant.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant is required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨.

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes x No ¨.

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 64,970,023 shares of Common Stock, par value $.01 per share, as of April 30, 2004, excluding 12,926,563 shares held by the registrant, its subsidiaries and certain Company trusts that are not entitled to vote. As a result of Lyondell Chemical Company’s November 30, 2004 acquisition of the registrant, there is no established public trading market for the registrant’s equity securities.

MILLENNIUM CHEMICALS INC.

TABLE OF CONTENTS


			Page
	Explanatory Note		2

Part I	FINANCIAL INFORMATION

	Item 1	Financial Statements	4

	Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26

	Item 4	Controls and Procedures	39

Part II	OTHER INFORMATION

	Item 6	Exhibits and Reports on Form 8-K	43

	Signature		44

Explanatory Note

Millennium Chemicals Inc. (the “Company”) filed Amendment No. 2 to its Annual Report on Form 10-K/A for the year ended December 31, 2003 (“Amendment No. 2”) on August 9, 2004 to reflect the restatement of its financial statements for the years ended December 31, 2001 through 2003. That restatement (the “August 2004 Restatement”) corrected errors in the computation of deferred income taxes relating to the Company’s investment in Equistar Chemicals, LP (“Equistar”), a partnership in which the Company owns a 29.5% interest. The August 2004 Restatement decreased the Company’s liability for deferred income taxes and Shareholders’ deficit at December 31, 2003 and 2002 by $15 million. The August 2004 Restatement similarly decreased liabilities for deferred income taxes and increased Shareholders’ equity at December 31, 2001 and 2000 by $15 million. The August 2004 Restatement did not affect the Company’s cash flow or operating income in any year. For more information on the effect of the August 2004 Restatement for each period presented see Note 17 to the Consolidated Financial Statements.

The Company is filing this Amendment No. 4 to its Quarterly Report on Form 10-Q/A for the period ended March 31, 2004 (“Amendment No. 4”) to restate its financial statements for the first quarter of 2004. Included herein are restated consolidated statements of operations and statements of cash flows for the three month periods ended March 31, 2004 and 2003 and restated consolidated balance sheets as of March 31, 2004 and December 31, 2003. This restatement (the “February 2005 Restatement”) corrects errors made in recording estimated liabilities for future environmental remediation spending associated with existing obligations, primarily related to the Kalamazoo River Superfund Site, that were not recorded previously. The February 2005 Restatement increased environmental remediation liabilities by $49 million, decreased deferred tax liabilities by $16 million, and increased Accumulated deficit by $33 million as of March 31, 2004, and increased net loss by $2 million, or $0.03 per share, and $1 million, or $0.01 per share, respectively, for the three months ended March 31, 2004 and 2003. The Company has also made certain adjustments to the financial statements for the periods presented that previously had been considered immaterial to those financial statements. For more information on the effect of the February 2005 Restatement for each period presented, see Note 18 to the Consolidated Financial Statements.

The company concluded, in January 2005, that it would restate its financial statements for the three months ended March 31, 2004 because of the errors that are corrected in the February 2005 Restatement. The conclusion was reached, as a result of an analysis of environmental remediation liabilities conducted in connection with Lyondell Chemical Company’s (“Lyondell”) acquisition of the Company on November 30, 2004, and the preparation of the financial statements of Lyondell and the Company as of and for the year ended December 31, 2004. These errors were reported by the Company on February 1, 2005, in a press release, a copy of which was filed as an exhibit to a Current Report on Form 8-K filed on February 2, 2005.

A discussion of the February 2005 Restatement is set forth in Note 18 to the Consolidated Financial Statements included in this Amendment No. 4. Changes also have been made to the following items in this Amendment No. 4 as a result of the February 2005 Restatement:

•

Item 1, Financial Statements has been revised to reflect the February 2005 Restatement;

•

Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations has been revised to reflect the February 2005 Restatement; and

•

Item 4, Controls and Procedures has been updated in connection with the errors discussed above.

On November 30, 2004, the Company was acquired by Lyondell. As a result, the Company is a wholly owned subsidiary of Lyondell. This Amendment No. 4 does not reflect events, including Lyondell’s November 30, 2004 acquisition of the Company, that have occurred after May 14, 2004, the date the Quarterly Report on Form 10-Q was originally filed. Information with respect to events that have occurred after May 14, 2004, has been or will be set forth, as appropriate, in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any references to facts and circumstances at a “current” date refer to such facts and circumstances as of such original filing date. This Amendment No. 4 consists of relevant portions of the Company’s prior filing of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2004, as previously amended, as prepared by the Company’s prior management. The Company is under new management following the acquisition of the Company by Lyondell on November 30, 2004.

The Company is also filing with the Securities and Exchange Commission, amendments to its Annual Report on Form 10-K/A for the year ended December 31, 2003, and is filing, as soon as practicable, amendments to its Quarterly Reports on Form 10-Q/A for each of the three months ended June 30 and September 30, 2004, to reflect changes required as a result of the February 2005 Restatement.

The only changes made to the prior disclosures in this Amendment No. 4 are those that were determined necessary by the Company’s new management as a result of the February 2005 Restatement. The Company has provided and will continue to provide current information as appropriate through filings on Form 8-K, as well as through the new filings on Form 10-Q referred to above. Also, the Company’s new management is preparing the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, which, in many respects, may update and supersede the information included in this Amendment No. 4 and the Company’s prior periodic reports, including regarding environmental liabilities.

In this Amendment No. 4, the terms “our”, “we”, and “the Company” refer to Millennium Chemicals Inc. and its consolidated subsidiaries, except as the context otherwise requires.

Non-GAAP Financial Measures

Financial measures based on accounting principles generally accepted in the United States of America (“GAAP”) are commonly referred to as GAAP financial measures. A non-GAAP financial measure is generally defined by the Securities and Exchange Commission as one that purports to measure historical or future financial performance, financial position, or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. From time to time the Company discloses non-GAAP financial measures, primarily EBITDA. EBITDA represents income from operations before interest, taxes, depreciation and amortization, other income items, equity earnings, and the cumulative effect of accounting changes. EBITDA is a key measure used by the banking and investing communities in their evaluation of economic performance. Accordingly, management believes that disclosure of EBITDA provides useful information to investors because it is frequently cited by financial analysts in evaluating companies’ performance. EBITDA identified above is not a measure of operating performance computed in accordance with GAAP and should not be considered as a substitute for GAAP measures. Additionally, these measures may not be comparable to similarly named measures of other companies.

The Company also periodically reports adjusted net or operating income (loss) or adjusted EBITDA, excluding designated items. Management believes that excluding these items generally helps investors to compare operating performance between two periods. Such adjusted data are not reported without an explanation of the items that are excluded.

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements (Unaudited)

MILLENNIUM CHEMICALS INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Millions, except share data)


	March 31, 2004			December 31, 2003
	(Restated -See Notes 17 and 18)
ASSETS
Current assets
Cash and cash equivalents	$	196		$	209
Trade receivables, net		323			277
Inventories		417			457
Other current assets		77			65

Total current assets		1,013			1,008
Property, plant and equipment, net		753			766
Investment in Equistar		471			469
Other assets		54			51
Goodwill		104			104

Total assets	$	2,395		$	2,398

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Notes payable	$	6		$	—
Current maturities of long-term debt		5			6
Trade accounts payable		260			236
Income taxes payable		3			5
Accrued expenses and other liabilities		148			126

Total current liabilities		422			373
Long-term debt		1,409			1,461
Deferred income taxes		253			257
Other liabilities		373			371

Total liabilities		2,457			2,462

Commitments and contingencies (Note 13)
Minority interest		28			27
Shareholders’ deficit
Preferred stock (par value $.01 per share, authorized 25,000,000 shares, none issued and outstanding)		—			—
Common stock (par value $.01 per share, authorized 225,000,000 shares; issued 77,896,586 shares at March 31, 2004 and December 31, 2003)		1			1
Paid in capital		1,289			1,292
Accumulated deficit		(1,007	)		(995	)
Accumulated other comprehensive loss		(131	)		(141	)
Treasury stock, at cost (13,224,871 and 13,905,687 shares at March 31, 2004 and December 31, 2003, respectively)		(247	)		(260	)
Unearned restricted shares		(2	)		(1	)
Deferred compensation		7			13

Total shareholders’ deficit		(90	)		(91	)

Total liabilities and shareholders’ deficit	$	2,395		$	2,398

See Notes to Consolidated Financial Statements (Unaudited).

MILLENNIUM CHEMICALS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(Millions, except per share data)


	Three Months Ended March 31,
	2004			2003
	(Restated - See Notes 17 and 18)
Net sales	$	465		$	415
Operating costs and expenses
Cost of products sold		388			331
Depreciation and amortization		24			27
Selling, development and administrative expense		36			31
Asset impairment charges		3			—
Combination costs		3			—
Reorganization and office closure costs		1			—

Operating income		10			26
Interest expense		(27	)		(23	)
Interest income		2			1
Earnings (loss) on Equistar investment		2			(43	)
Other expense, net		(1	)		—

Loss before income taxes, minority interest and cumulative effect of accounting change		(14	)		(39	)
Benefit from income taxes		3			15

Loss before minority interest and cumulative effect of accounting change		(11	)		(24	)
Minority interest		(1	)		(3	)

Loss before cumulative effect of accounting change		(12	)		(27	)
Cumulative effect of accounting change		—			(1	)

Net loss	$	(12	)	$	(28	)

Basic and diluted loss per share:
Before cumulative effect of accounting change	$	(0.19	)	$	(0.42	)
From cumulative effect of accounting change		—			(0.02	)

After cumulative effect of accounting change	$	(0.19	)	$	(0.44	)

See Notes to Consolidated Financial Statements (Unaudited).

MILLENNIUM CHEMICALS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Millions)


	Three Months Ended March 31,
	2004			2003
	(Restated -See Notes 17 and 18)
Cash flows from operating activities:
Net loss	$	(12	)	$	(28	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Cumulative effect of accounting change		—			1
Asset impairment charges		3			—
Depreciation and amortization		24			27
Deferred income tax benefit		(6	)		(21	)
(Earnings) loss on Equistar investment		(2	)		43
Minority interest		1			3
Other, net		(9	)		(2	)
Changes in assets and liabilities:
Increase in trade receivables		(44	)		(13	)
Decrease in inventories		41			18
(Increase) decrease in other current assets		(8	)		1
Increase (decrease) in trade accounts payable		25			(36	)
Increase in accrued expenses and other liabilities and income taxes payable		27			4
Decrease in other liabilities		(2	)		(11	)

Cash provided by (used in) operating activities		38			(14	)

Cash flows from investing activities:
Capital expenditures		(10	)		(8	)

Cash used in investing activities		(10	)		(8	)

Cash flows from financing activities:
Dividends to shareholders		—			(9	)
Proceeds from long-term debt		16			96
Repayment of long-term debt		(70	)		(66	)
Increase (decrease) in notes payable and other short term borrowings		5			(1	)
Proceeds from exercise of stock options		3			—

Cash (used in) provided by financing activities		(46	)		20

Effect of exchange rate changes on cash		5			2

Decrease in cash and cash equivalents		(13	)		—
Cash and cash equivalents at beginning of year		209			125

Cash and cash equivalents at end of period	$	196		$	125

See Notes to Consolidated Financial Statements (Unaudited).

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Dollars in millions, except share data)

Note 1 – Basis of Presentation

Pursuant to the rules and regulations of the Securities and Exchange Commission, the accompanying unaudited interim consolidated financial statements do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America for complete financial statements. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and disclosures included in the Annual Report on Form 10-K of Millennium Chemicals Inc. (the “Company”) for the year ended December 31, 2003, as amended by Amendment No. 5 on Form 10-K/A filed with the Securities and Exchange Commission on February 14, 2005. In the opinion of management, all adjustments considered necessary to present fairly the financial position and results of operations for the interim periods are included in the accompanying unaudited consolidated financial statements.

The unaudited consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. Minority interest represents the minority ownership of the Company’s Brazilian subsidiary and the La Porte Methanol Company. All significant intercompany accounts and transactions have been eliminated. The Company’s 29.5% investment in Equistar Chemicals, LP (“Equistar”), a joint venture between the Company and Lyondell Chemical Company (“Lyondell”), is accounted for by the equity method; accordingly, the Company’s share of Equistar’s pre-tax net income or loss is included in net income or loss.

Note 2 – Agreement for a Stock-for-Stock Business Combination

On March 29, 2004, Lyondell and the Company announced that their Boards of Directors had approved, and the companies had executed, a definitive agreement for a stock-for-stock business combination of the companies, expected to be tax-free to the Company, Lyondell and their respective shareholders.

The Company’s shareholders will receive between 0.95 and 1.05 shares of Lyondell common stock for each share of the Company’s Common Stock, depending on the volume-weighted average price for the Lyondell shares for the 20 trading days ending on the third trading day before closing. The Company’s shareholders will receive 0.95 shares of Lyondell stock if the average Lyondell stock price is $20.50 per share or greater, and 1.05 shares if it is $16.50 per share or less. Between the two prices, the exchange ratio varies proportionately. The new shares will be entitled to receive the same cash dividend as existing outstanding Lyondell shares. The Company’s 4.00% convertible senior debentures (the “4.00% Convertible Senior Debentures”) will become convertible into Lyondell common stock in accordance with the terms of the convertible debenture indenture following the closing of the transaction.

The transaction is subject to customary conditions, including approval by both companies’ shareholders and receipt of required regulatory approvals and amendments to each of Lyondell’s and the Company’s credit agreements and Lyondell’s receivables sales facility. The transaction is expected to close in the third quarter of 2004. The transaction involves the merger of Millennium Subsidiary LLC, a newly created subsidiary of the Company, into the Company, in which the Company’s Common Stock now held by its public shareholders will be converted into common stock of Lyondell, and the Company’s preferred stock to be issued to Lyondell immediately before the merger will be converted into common stock of the surviving entity. As a result, the Company will become a wholly-owned subsidiary of Lyondell. After the close of the transaction, the combined company will be called “Lyondell Chemical Company” and will be headquartered in Houston, Texas.

For the three months ended March 31, 2004, the Company has incurred approximately $3 of professional services costs in connection with the proposed combination, which are included in Combination costs in the accompanying unaudited Consolidated Statements of Operations.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 3 – Loss per Share and Stock-Based Compensation

The weighted-average number of equivalent shares of common stock outstanding used in computing loss per share is as follows:


	Three Months Ended March 31,
	2004	2003
Weighted-average common stock outstanding – basic and diluted	64,497,266	63,852,822

The calculation of diluted loss per share for the three months ended March 31, 2004 does not include 83,119 restricted shares, 135,211 options to purchase Common Stock, 196,050 shares held in trust for the Company’s employee benefit plans, and shares associated with the Company’s 4.00% Convertible Senior Debentures, as more fully described in Note 9. The calculation of diluted loss per share for the three months ended March 31, 2003 does not include 53,957 restricted shares and 219,140 shares held in trust for the Company’s employee benefit plans. The effect of including these options and shares would be antidilutive due to the reported net losses in each of these periods.

Statement of Financial Accounting Standards (“SFAS”) No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”), encourages a fair value based method of accounting for employee stock options and similar equity instruments, which generally would result in the recording of additional compensation expense in the Company’s financial statements. SFAS No. 123 also allows the Company to continue to account for stock-based compensation using the intrinsic value for equity instruments under Accounting Principles Board Opinion No. 25 (“APB Opinion No. 25”). The Company has elected to account for such instruments using APB Opinion No. 25 and related interpretations, and thus has adopted the disclosure-only provisions of SFAS No. 123. Accordingly, no compensation cost has been recognized for the stock option plans in the accompanying financial statements as all options granted had an exercise price equal to the market value of the underlying Common Stock on the date of grant.

Disclosure on a pro forma basis of net loss and related per-share amounts as if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based compensation is omitted because the effect on pro forma net loss is not significant.

Note 4 – Recent Accounting Developments

On January 1, 2003, the Company adopted SFAS No. 143, “Accounting for Asset Retirement Obligations” (“SFAS No. 143”). SFAS No. 143 applies to legal obligations associated with the retirement of long-lived assets. This standard requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred and the associated asset retirement costs be capitalized as part of the carrying amount of the long-lived asset. Accretion expense and depreciation expense related to the liability and capitalized asset retirement costs, respectively, are recorded in subsequent periods. The Company’s asset retirement obligations arise from activities associated with the eventual remediation of sites used for landfills and mining and include estimated liabilities for closure, restoration, and post-closure care. None of the Company’s assets are legally restricted for purposes of settling these obligations. As these liabilities are settled, a gain or loss is recognized for any difference between the settlement amount and the liability recorded. The amount of the asset retirement obligations was $13 at each of March 31, 2004 and December 31, 2003. The Company reported an after-tax transition charge of $1 in the first quarter of 2003 as the cumulative effect of this accounting change. The impact of adoption was to increase the Company’s reported assets and liabilities by $2 and $3, respectively.

In December 2003, the Financial Accounting Standards Board (“FASB”) issued revised FASB Interpretation No. 46, “Consolidation of Variable Interest Entities, an interpretation of Accounting Research Bulletin No. 51, ‘Consolidated Financial Statements’” (“FIN 46R”). FIN 46R requires the assets, liabilities, and results of operations of a variable interest entity (“VIE”) to be consolidated in the financial statements of the enterprise considered to be the primary beneficiary of that entity. The Company evaluated material relationships with certain entities that were considered potential VIEs. The Company concluded, with one possible exception discussed below, that those entities are not VIEs or the Company is not the primary beneficiary of the VIE. As such, in accordance with FIN 46R, the Company is not required to consolidate those entities.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 4 – Recent Accounting Developments — (Continued)

The Company evaluated its long-term obligations with one entity that may be a VIE. The Company has no equity interest in this entity and has confirmed that the entity is consolidated by an equity owner. The Company has not been able to obtain the financial information from the entity necessary to determine whether the Company is the primary beneficiary of the entity. Management of the entity cited confidentiality considerations with regard to the decision not to provide the Company with certain financial information. The Company pays approximately $3 in plant and equipment rental charges on an annual basis to this entity.

In March 2004, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF Issue No. 03-6, “Participating Securities and the Two-Class Method under FASB Statement No. 128, Earnings per Share” (“EITF 03-6”). EITF 03-6 addresses a number of questions regarding the computation of earnings per share by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of the company when, and if, it declares dividends on its common stock. EITF 03-6 becomes effective for periods beginning after March 31, 2004. The Company is currently evaluating the impact of implementing EITF 03-6 on its financial statements.

In January 2004, the FASB issued FASB Staff Position (“FSP”) No. FAS 106-1, “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003” (“FSP No. FAS 106-1”). FSP No. FAS 106-1 permits a sponsor of a postretirement healthcare plan that provides a prescription drug benefit to make a one-time election to defer recognition and accounting for the effects of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “Medicare Act of 2003”), which was signed into law on December 8, 2003, under SFAS No. 106, “Employers’ Accounting for Postretirement Benefits Other Than Pensions” and SFAS No. 109, “Accounting for Income Taxes” as well as in making disclosures related to its plans as required by SFAS No. 132 (Revised 2003), “Employers’ Disclosures about Pensions and Other Postretirement Benefits” until the FASB develops and issues authoritative guidance on accounting for the Federal subsidies provided by the Medicare Act of 2003. The Medicare Act of 2003 introduces a prescription drug benefit under Medicare (“Medicare Part D”) as well as a Federal subsidy to sponsors of retiree healthcare benefit plans that provide a medical benefit that is at least actuarially equivalent to Medicare Part D. The Company elected to make the one-time deferral and, accordingly, the measures of its accumulated postretirement benefit obligation and net periodic postretirement benefit cost included in its financial statements and accompanying notes thereto do not reflect the effects of the Medicare Act of 2003. On March 16, 2004, the FASB issued proposed FSP No. FAS 106-b, “Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003” (“Proposed FSP No. FAS 106-b”). The Proposed FSP No. FAS 106-b provides guidance on the accounting for the effects of the Medicare Act of 2003 for employers that sponsor postretirement healthcare plans that provide prescription drug benefits, including related income tax accounting and rules for transition, under which some companies may have to restate previous quarters’ financial statements in certain circumstances. If the Proposed FSP No. FAS 106-b is approved, its provisions will go into effect for most companies as of the first interim or annual period beginning after June 15, 2004. The Company is currently evaluating the possible economic effects of the Medicare Act of 2003, if any, on its postretirement benefit plan accounting.

Note 5 – Asset Impairment Charges

Asset impairment charges in the first quarter of 2004 of $3 represented the write off of expenditures for property, plant and equipment at the Company’s Le Havre, France TiO₂ manufacturing plant. In the fourth quarter of 2003, the carrying value of the property, plant and equipment at the Le Havre TiO₂ manufacturing plant was determined to be impaired, and a charge was required to write down the basis in those assets to zero. Capital expenditures at this plant for the three months ended March 31, 2004 were capitalized as property, plant and equipment and then immediately written off as asset impairment charges as a result of evaluating those assets for impairment under the guidance of SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”. Since the basis of all of the property, plant and equipment for this plant has been written down to zero, no depreciation expense for this plant is recorded in manufacturing and other costs of sales.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 6 – Reorganization and Office Closure Costs

On July 21, 2003, the Company announced that it would implement a program to reduce costs. This program included a reduction of approximately 5% in the number of the Company’s employees worldwide. The Company closed its executive offices in Red Bank, New Jersey, effective September 1, 2003, and relocated its headquarters to Hunt Valley, Maryland, where the Company has existing administrative offices. In addition, the Company announced the suspension of payment of dividends on its Common Stock.

The Company has recorded cumulative charges related to the program of $19 (including $1 for the three months ended March 31, 2004), of which $18 was for severance-related costs and $1 was for contractual commitments for ongoing lease costs, net of expected sublease income, associated with the closure of the Red Bank, New Jersey office for the remaining term of the lease agreement. All costs associated with this program are accounted for in accordance with SFAS No. 112, “Employer’s Accounting for Postemployment Benefits” or SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities”, as appropriate. Cumulative severance-related cash payments of $22 for the implementation of this program were made through March 31, 2004, including $8 in the first quarter of 2004. Substantially all of the remainder of the cash payments relating to this program, which are estimated to be approximately $4, will be disbursed during the next several quarters. No significant charges associated with this program are expected in future periods. Accrued liabilities associated with this program and included in Accrued expenses and other liabilities were $2 at March 31, 2004. The cumulative charges of $19 associated with the cost reduction program are less than the cumulative severance-related cash payments of $22 because some of the cash payments made under the program, primarily for retirement benefits, were related to expenses and liabilities that were recorded through the normal course of business in periods prior to the implementation of this program in mid-2003.

Note 7 – European Receivables Securitization Program

From March 2002 until November 2003, the Company had been transferring its interest in certain European trade receivables to an unaffiliated third party as its basis for issuing commercial paper under a revolving securitization arrangement (annually renewable for a maximum of five years on April 30 of each year at the option of the third party) with maximum availability of 70 million euro, which was treated, in part, as a sale under accounting principles generally accepted in the United States of America. In November 2003, the Company terminated this securitization arrangement and there were no balances outstanding at March 31, 2004 or December 31, 2003. The cumulative gross proceeds from this securitization arrangement through March 31, 2003 was $95. Cash flows from this securitization arrangement were reflected as operating activities in the Consolidated Statement of Cash Flows. For the quarter ended March 31, 2003, the aggregate loss on sale associated with this arrangement was $1 and was included in selling, development and administrative (“S,D&A”) costs. Servicing liabilities associated with the transaction were not significant.

Note 8 – Inventories

Inventories are stated at the lower of cost or market value.


	March 31, 2004		December 31, 2003
Finished products	$	240	$	258
In-process products		36		38
Raw materials		73		96
Maintenance parts and supplies		68		65

	$	417	$	457

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 9 – Long-Term Debt and Credit Arrangements

The maturities of the Company’s long-term debt through 2009 and thereafter are as follows:


	April 1 - December 31, 2004		2005		2006		2007		2008		2009		Thereafter		Total at March 31, 2004			Total at December 31, 2003
Revolving loans	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—		$	52
7.00% Senior Notes		—		—		500		—		—		—		—		500			500
7.625% Senior Debentures		—		—		—		—		—		—		250		250			250
9.25% Senior Notes		—		—		—		—		475		—		—		475			475
4.00% Convertible Senior Debentures		—		—		—		—		—		—		150		150			150
Other long-term debt		4		5		5		2		1		1		3		21			23

Maturities of long-term debt	$	4	$	5	$	505	$	2	$	476	$	1	$	403		1,396			1,450

Non-cash components of long-term debt																18			17

Total debt																1,414			1,467
Less: current maturities of long-term debt																(5	)		(6	)

Total long-term debt															$	1,409		$	1,461

On November 25, 2003, the Company received approximately $125 in gross proceeds and, on December 2, 2003, received an additional $25 in gross proceeds from the sale by Millennium Chemicals Inc. (“Millennium Chemicals”) of $150 aggregate principal amount of the 4.00% Convertible Senior Debentures, which are guaranteed by Millennium America Inc. (“Millennium America”), a wholly-owned indirect subsidiary of Millennium Chemicals. The gross proceeds of the sale were used to repay all of the $47 of outstanding borrowings at that time under the term loan portion (the “Term Loan”) of the Company’s five-year credit agreement expiring June 18, 2006 (the “Credit Agreement”) and $103 of outstanding borrowings under the revolving loan portion (the “Revolving Loans”) of its Credit Agreement, which currently has a maximum availability of $150. The Company used $4 of cash to pay the fees relating to the sale of the 4.00% Convertible Senior Debentures.

On April 25, 2003, the Company received approximately $107 in net proceeds ($109 in gross proceeds) from the issuance and sale by Millennium America of $100 additional principal amount at maturity of its 9.25% Senior Notes due June 15, 2008 (the “9.25% Senior Notes”), which are guaranteed by Millennium Chemicals. The net proceeds were used to repay all of the $85 of outstanding borrowings at that time under the Revolving Loans and for general corporate purposes. Millennium Chemicals and Millennium America guarantee the obligations under the Credit Agreement. Under the terms of this issuance and sale, Millennium America and Millennium Chemicals entered into an exchange and registration rights agreement with the initial purchasers of the $100 additional principal amount of these 9.25% Senior Notes. Pursuant to this agreement, each of Millennium America and Millennium Chemicals agreed to: (1) file with the Securities and Exchange Commission on or before July 24, 2003 a registration statement relating to a registered exchange offer for the notes, and (2) use its reasonable efforts to cause this exchange offer registration statement to be declared effective under the Securities Act on or before October 22, 2003. On June 13, 2003, Millennium America and Millennium Chemicals, as guarantor, initially filed a registration statement with the Securities and Exchange Commission, and on December 15, 2003, filed an amended registration statement. However, as of March 31, 2004, the exchange offer registration statement had not yet been declared effective. As a result, since October 22, 2003, Millennium America has been obligated to pay additional interest at the annualized rate of approximately 1.00% to each holder of the $100 additional amount of notes. This additional interest will be paid until such time as the registration statement becomes effective.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 9 – Long-Term Debt and Credit Arrangements — (Continued)

The Company had $21 of outstanding undrawn standby letters of credit and no outstanding borrowings under the Revolving Loans and, accordingly, had $129 of unused availability under such facility at March 31, 2004. In addition to letters of credit outstanding under the Credit Agreement, the Company also had outstanding undrawn standby letters of credit and bank guarantees under other arrangements of $6 at March 31, 2004. The Company had unused availability under short-term uncommitted lines of credit, other than the Credit Agreement, of $43 at March 31, 2004.

The Revolving Loans are available in US dollars, British pounds and euros. The Revolving Loans may be borrowed, repaid and reborrowed from time to time. The Revolving Loans include a $50 letter of credit subfacility and a swingline facility in the amount of $25. As of March 31, 2004, $21 was outstanding under the letter of credit subfacility, and no amount under the swingline facility. The Term Loans were entirely prepaid on November 25, 2003, which effectively retired the Term Loans as any such amounts prepaid may not be reborrowed. The interest rates on the Revolving Loans and the Term Loans are floating rates based upon margins over LIBOR, NIBOR, or the Administrative Agent’s prime lending rate, as the case may be. Such margins, as well as the facility fee, are based on the Company’s Leverage Ratio, as defined.

The Credit Agreement contains various restrictive covenants and requires that the Company meet certain financial performance criteria. Compliance with these covenants is monitored frequently in order to assess the likelihood of continued compliance. As a result of the restatement of its prior financial statements, the Company obtained a waiver on July 29, 2004, and February 2, 2005, under the Credit Agreement relating to certain representations under the Credit Agreement regarding such prior financial statements. The Company was in compliance with all covenants under the Credit Agreement in effect at March 31, 2004.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 9 – Long-Term Debt and Credit Arrangements — (Continued)

such asset sales in excess of $100 from November 18, 2003, the effective date of the fourth quarter 2003 amendment. Any sale involving Equistar or certain inventory or accounts receivable will reduce the maximum availability under the Credit Agreement by 100% of such Net Cash Proceeds received. The obligations under the Credit Agreement are collateralized by: (1) a pledge of 100% of the stock of the Company’s existing and future domestic subsidiaries and 65% of the stock of certain of the Company’s existing and future foreign subsidiaries, in both cases other than subsidiaries that hold immaterial assets (as defined in the Credit Agreement); (2) all the equity interests held by the Company’s subsidiaries in Equistar and the La Porte Methanol Company (which pledges are limited to the right to receive distributions made by Equistar and the La Porte Methanol Company, respectively); and (3) all present and future accounts receivable, intercompany indebtedness and inventory of the Company’s domestic subsidiaries, other than subsidiaries that hold immaterial assets. As a result of the announced stock-for-stock business combination with Lyondell, the Company will have to obtain amendments or waivers of certain provisions of its Credit Agreement prior to the closing of the proposed transaction. At a minimum, the Company expects that it will have to obtain a waiver of Section 6.05 of the Credit Agreement, which relates to the covenant that the Company will not consolidate with or merge into any other person or sell or otherwise dispose of certain assets, as defined, and Section 7(m), which relates to a Change in Control triggering an Event of Default, each as defined.

Millennium America also has outstanding $500 aggregate principal amount of 7.00% Senior Notes due November 15, 2006 (the “7.00% Senior Notes”) and $250 aggregate principal amount of 7.625% Senior Debentures due November 15, 2026 (the “7.625% Senior Debentures” and, together with the 7.00% Senior Notes and the 9.25% Senior Notes the “Senior Notes”), that are fully and unconditionally guaranteed by Millennium Chemicals. The indenture under which the 7.00% Senior Notes and 7.625% Senior Debentures were issued contains certain covenants that limit, among other things: (i) the ability of Millennium America and its Restricted Subsidiaries (as defined) to grant liens or enter into sale/leaseback transactions; (ii) the ability of the Restricted Subsidiaries to incur additional indebtedness; and (iii) the ability of Millennium America and Millennium Chemicals to merge, consolidate or transfer substantially all of their respective assets. This indenture allows Millennium America and its Restricted Subsidiaries, as defined, to grant security on loans of up to 15% of Consolidated Net Tangible Assets (“CNTA”), as defined, of Millennium America and its consolidated subsidiaries. Accordingly, based upon CNTA and secured borrowing levels at March 31, 2004, any reduction in CNTA below approximately $1,000 would decrease the Company’s availability under the Revolving Loans by 15% of any such reduction. CNTA was approximately $2,000 at March 31, 2004. The 7.00% Senior Notes and the 7.625% Senior Debentures can be accelerated by the holders thereof if any other debt in excess of $20 is in default and is accelerated.

The 9.25% Senior Notes were issued by Millennium America and are guaranteed by Millennium Chemicals. The indenture under which the 9.25% Senior Notes were issued contains certain covenants that limit, among other things, the ability of the Company and/or certain subsidiaries of the Company to: (i) incur additional debt; (ii) issue redeemable stock and preferred stock; (iii) create liens; (iv) redeem debt that is junior in right of payment to the 9.25% Senior Notes; (v) sell or otherwise dispose of assets, including capital stock of subsidiaries; (vi) enter into arrangements that restrict dividends from subsidiaries; (vii) enter into mergers or consolidations; (viii) enter into transactions with affiliates; and (ix) enter into sale/leaseback transactions. In addition, this indenture contains a covenant that would prohibit the Company from (i) paying dividends or making distributions on its common stock; (ii) repurchasing its common stock; and (iii) making other types of restricted payments, including certain types of investments, if such restricted payments would exceed a “restricted payments basket.” Although the Company has no intention at the present time to pay dividends or make distributions, repurchase its Common Stock, or make other restricted payments, the Company would be prohibited by this covenant from making any such payments at the present time. The indenture also requires the calculation of a Consolidated Coverage Ratio, defined as the ratio of the aggregate amount of EBITDA, as defined, for the four most recent fiscal quarters to Consolidated Interest Expense, as defined, for the four most recent quarters. The Company must maintain a Consolidated Coverage Ratio of 2.25 to 1.00. Currently, the Company’s Consolidated Coverage Ratio is below this threshold and, therefore, the Company is subject to certain restrictions that limit the Company’s ability to incur additional indebtedness, pay dividends, repurchase capital stock, make certain other restricted payments, and enter into mergers or consolidations. However, if the 9.25% Senior Notes were to receive investment grade credit ratings from both Moody’s Investors Service (“Moody’s”) and Standard & Poor’s (“S&P”) and meet certain other requirements as specified in the indenture, certain of these covenants would no longer apply. The 9.25% Senior Notes can be accelerated by the holders thereof if any other debt in excess of $30 is in default and is accelerated.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 9 – Long-Term Debt and Credit Arrangements — (Continued)

The consummation of the announced stock-for-stock business combination with Lyondell is expected to give each holder of the 9.25% Senior Notes the right to require the Company to purchase all or part of such holder’s securities at a purchase price in cash equal to 101% of the principal amount thereof plus accrued and unpaid interest to the date of purchase.

The 4.00% Convertible Senior Debentures were issued by Millennium Chemicals and are guaranteed by Millennium America. Holders may convert their debentures into shares of the Company’s Common Stock at a conversion price, subject to adjustment upon certain events, of $13.63 per share, which is equivalent to a conversion rate of 73.3568 shares per one thousand dollar principal amount of debentures. The conversion privilege may be exercised under the following circumstances:

•

prior to November 15, 2018, during any fiscal quarter commencing after December 31, 2003, if the closing price of the Company’s Common Stock on at least 20 of the 30 consecutive trading days ending on the first trading day of that quarter is greater than 125% of the then current conversion price;

•

on or after November 15, 2018, at any time after the closing price of the Company’s Common Stock on any date is greater than 125% of the then current conversion price;

•

if the debentures are called for redemption;

•

upon the occurrence of specified corporate transactions, including a consolidation, merger or binding share exchange pursuant to which the Company’s Common Stock would be converted into cash or property other than securities;

•

during the five business-day period after any period of ten consecutive trading days in which the trading price per one thousand dollar principal amount of debentures on each day was less than 98% of the product of the last reported sales price of the Company’s Common Stock and the then current conversion rate; and

•

at any time when the long-term credit rating assigned to the debentures is either Caa1 or lower, in the case of Moody’s, or B- or lower in the case of S&P, or either rating agency has discontinued, withdrawn or suspended its rating.

The debentures are redeemable at the Company’s option beginning November 15, 2010 at a redemption price equal to 100% of their principal amount, plus accrued interest, if any. On November 15 in each of 2010, 2013 and 2018, holders of debentures will have the right to require the Company to repurchase all or some of the debentures they own at a purchase price equal to 100% of their principal amount, plus accrued interest, if any. The Company may choose to pay the purchase price in cash or shares of the Company’s Common Stock or any combination thereof. In the event of a conversion request upon a credit ratings event as described above, after June 18, 2006, the Company has the right to deliver, in lieu of shares of Common Stock, cash or a combination of cash and shares of Common Stock. Holders of the debentures will also have the right to require the Company to repurchase all or some of the debentures they own at a cash purchase price equal to 100% of their principal amount, plus accrued interest, if any, upon the occurrence of certain events constituting a Fundamental Change, as defined in the indenture. This indenture also limits the Company’s ability to consolidate with or merge with or into any other person, or sell, convey, transfer or lease properties and assets substantially as an entirety to another person, except under certain circumstances. The consummation of the announced stock-for-stock business combination with Lyondell is not expected to be considered a Fundamental Change, as defined in the indenture. However, the Company does expect to be required to execute with the trustee a supplemental indenture providing that each debenture shall be convertible into Lyondell’s common stock at a conversion ratio, as adjusted in accordance with the Agreement of Merger between the Company and Lyondell.

Although the Company does not currently pay a dividend to its common stockholders, Lyondell does currently pay a dividend. If the Company executes a supplemental indenture with the trustee, as described above, and Lyondell continues to pay a dividend to its common stockholders, the conversion rate, as defined, will be adjusted. The conversion rate will be increased by a percentage calculated by dividing the average of the last reported sales price of Common Stock for the ten consecutive trading days prior to the business day immediately preceding the record date by this average less the amount in cash per share that Lyondell distributes to holders of

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 9 – Long-Term Debt and Credit Arrangements — (Continued)

Common Stock. At the current market prices of Lyondell common stock, this percentage would be approximately 1.4% per quarter.

At March 31, 2004, the Company was in compliance with all covenants in the indentures governing the 9.25% Senior Notes, 7.00% Senior Notes, 7.625% Senior Debentures, and 4.00% Convertible Senior Debentures.

The Company, as well as the Senior Notes and the 4.00% Convertible Senior Debentures are currently rated BB- by S&P with a stable outlook. Moody’s has assigned the Company a senior implied rating of Ba3, and the Senior Notes and the 4.00% Convertible Senior Debentures a rating of B1 with a negative outlook. These ratings are non-investment grade ratings.

On March 29, 2004, S&P placed the Company’s ratings on Credit Watch with negative implications reflecting the future ownership by the highly leveraged Lyondell and the strong likelihood that the ratings of the Company will be lowered modestly upon completion of the proposed transaction. On March 30, 2004, Moody’s placed the Company’s credit ratings under review for possible downgrade following the announcement by Lyondell and the Company that the two companies have signed a definitive agreement that, if completed, will result in the acquisition of the Company by Lyondell in a stock-for-stock transaction. Moody’s cited concerns over the potential impact that future distributions by the Company, as an operating subsidiary of Lyondell, to Lyondell will have on the Company’s credit profile over the long term, primarily the potential for elevated debt levels over the next several years while Lyondell seeks to de-lever its balance sheet.

Note 10 – Derivative Instruments and Hedging Activities

The Company is exposed to market risk, such as changes in currency exchange rates, interest rates and commodity pricing. To manage the volatility relating to these exposures, the Company selectively enters into derivative transactions pursuant to the Company’s policies for hedging practices. Designation is performed on a specific exposure basis to support hedge accounting. The changes in fair value of these hedging instruments are offset in part or in whole by corresponding changes in the fair value or cash flows of the underlying exposures being hedged. The Company does not hold or issue derivative financial instruments for speculative or trading purposes.

Foreign Currency Exposure Management: The Company manufactures and sells its products in a number of countries throughout the world and, as a result, is exposed to movements in foreign currency exchange rates. The primary purpose of the Company’s foreign currency hedging activities is to manage the volatility associated with foreign currency purchases and foreign currency sales. The Company utilizes forward exchange contracts with various terms. As of March 31, 2004, these contracts had expiration dates no later than October 25, 2004.

The Company utilizes forward exchange contracts with contract terms normally lasting less than three months to protect against the adverse effect that exchange rate fluctuations may have on foreign currency denominated trade receivables and trade payables. These derivatives have not been designated as hedges for accounting purposes. The gains and losses on both the derivatives and the foreign currency denominated trade receivables and payables are recorded in current earnings. Net amounts included in earnings, which offset similar amounts from foreign currency denominated trade receivables and payables, were gains of $2 for the three months ended March 31, 2004 and were not significant for the three months ended March 31, 2003.

In addition, the Company utilizes forward exchange contracts that qualify as cash flow hedges. These are intended to offset the effect of exchange rate fluctuations on forecasted sales and inventory purchases. Gains and losses on these instruments are deferred in other comprehensive income (“OCI”) until the underlying transaction is recognized in earnings. The earnings impact is reported either in Net sales or Cost of products sold to match the underlying transaction being hedged. Net amounts on forward exchange contracts designated as cash flow hedges reclassified to earnings to match the gain or loss on the underlying transaction being hedged were insignificant for each of the three months ended March 31, 2004 and 2003. Hedge ineffectiveness had no impact on earnings for the first quarter of 2004 or 2003. No forward exchange contract cash flow hedges were discontinued during the first quarter of 2004 or 2003. The Company currently estimates that net gains of approximately $1 on foreign currency cash flow hedges included in OCI at March 31, 2004 will be reclassified to earnings during the next twelve months.

Commodity Price Risk Management: Raw materials used by the Company are subject to price volatility caused by demand and supply conditions and other unpredictable factors. The Company selectively uses

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 10 – Derivative Instruments and Hedging Activities — (Continued)

commodity swap arrangements and commodity options with various terms to manage the volatility related to anticipated purchases of natural gas and certain commodities, a portion of which exposes the Company to natural gas price risk. As of March 31, 2004, there were no such contracts outstanding. The mark-to-market gains or losses on qualifying hedges were included in OCI to the extent effective, and reclassified into Cost of products sold in the period during which the hedged transaction affected earnings. The mark-to-market gains or losses on ineffective portions of hedges are recognized in Cost of products sold immediately. Net amounts on commodity swaps designated as cash flow hedges reclassified to Cost of products sold to match the gain or loss on the underlying transaction being hedged were insignificant for the three months ended March 31, 2004, and were gains of $1 for the three months ended March 31, 2003. Hedge ineffectiveness had no impact on earnings for the first quarter of 2004 or 2003. No commodity swap cash flow hedges were discontinued in the first quarter of 2004, and commodity swap cash flow hedges that were discontinued in the first quarter of 2003 were not significant. The Company had no gains or losses on commodity swaps included in OCI at March 31, 2004.

In addition, the Company utilizes commodity swap and option arrangements to manage price volatility related to anticipated purchases of certain commodities, a portion of which exposes the Company to natural gas price risk. These derivatives have not been designated as hedges for accounting purposes. The gains and losses on these instruments are recorded in current earnings. Net gains and losses included in earnings were not significant in each of the three months ended March 31, 2004 and 2003.

Interest Rate Risk Management: The Company selectively uses derivative instruments to manage its ratio of debt bearing fixed interest rates to debt bearing variable interest rates. At March 31, 2004, the Company had outstanding interest rate swap agreements with a notional amount of $225, which are designated as fair value hedges of underlying fixed-rate obligations. The fair value of these interest rate swap agreements was approximately $6 at March 31, 2004 resulting in an increase in the carrying value of long-term debt and the recognition of a corresponding swap asset. The gains and losses on both the interest rate swaps and the hedged portion of the underlying debt are recorded in Interest expense. Hedge ineffectiveness had no significant impact on earnings for the first quarter of 2004 or 2003.

Note 11 – Pension and Other Postretirement Benefits

The following table provides the components of net periodic benefit cost and the amount of contributions and benefits paid:


	Pension Benefits For the Three Months Ended March 31,						Other Postretirement Benefits For the Three Months Ended March 31,
	2004			2003			2004			2003
Net periodic benefit cost (income)
Service cost, including interest	$	3		$	3		$	—		$	—
Interest on PBO		13			13			—			1
Return on plan assets		(16	)		(17	)		—			—
Amortization of unrecognized net loss		3			2			—			—
Amortization of prior service cost		—			—			(1	)		—

Net periodic benefit cost (income)		3			1			(1	)		1
Defined contribution plans		1			1			—			—

Net periodic benefit cost (income)	$	4		$	2		$	(1	)	$	1

Company pension trust contributions	$	5		$	2

Company other postretirement benefits paid							$	3		$	2

The Company expects to contribute approximately $12 to pension plan trusts during 2004.

As a result of rising medical benefit costs and competitive business conditions, the Company announced in the first quarter of 2004 that, effective April 1, 2004, it will reduce the level of retiree medical benefits provided to

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 11 – Pension and Other Postretirement Benefits — (Continued)

essentially all of its retirees by offering a monthly subsidy to retirees that enroll in designated preferred provider organization plans or Medicare supplement insurance plans. This change will reduce the Company’s accumulated postretirement benefit obligation by approximately $45. Beginning in 2004, the Company is recognizing this reduction ratably over approximately thirteen years through other postretirement employee benefit (“OPEB”) net periodic benefit cost. Estimated OPEB net periodic benefit cost for the year ending December 31, 2004, after giving effect to this change, will be income of approximately $4 compared to a benefit cost of $2 for the year ended December 31, 2003. The Company estimates that cash payments for retiree medical and insurance benefits for the year ending December 31, 2004 will be approximately $11, which is slightly less than such payments made for the year ended December 31, 2003, as the Company transitions to the subsidy plan. Cash payments for retiree medical and insurance benefits in subsequent years are estimated to be significantly less than in 2003.

Note 12 – Comprehensive Income (Loss)

The following table sets forth the components of other comprehensive income and total comprehensive income (loss):


	Three Months Ended March 31,
	2004			2003
	Restated *			Restated *
Net loss	$	(12	)	$	(28	)
Other comprehensive income
Net gains (losses) on derivative financial instruments		1			(3	)
Currency translation adjustment		9			13

Total comprehensive income (loss)	$	(2	)	$	(18	)

*	The Company restated its financial statements ad disclosed in Notes 17 and 18 to the Consolidated Financial Statements in this Amendment No. 4.

Note 13 – Commitments and Contingencies

Legal and Environmental: The Company and various Company subsidiaries are defendants in a number of pending legal proceedings relating to present and former operations. These include several proceedings alleging injurious exposure of plaintiffs to various chemicals and other materials on the premises of, or manufactured by, the Company’s current and former subsidiaries. Typically, such proceedings involve claims made by many plaintiffs against many defendants in the chemical industry. Millennium Petrochemicals is one of a number of defendants in 100 active premises-based asbestos cases (i.e., where the alleged exposure to asbestos-containing materials was to employees of third-party contractors or subcontractors on the premises of certain facilities, and did not relate to any products manufactured or sold by the Company or any of its predecessors). Millennium Petrochemicals is responsible for these premises-based cases as a result of its indemnification obligations under the Company’s agreements with Equistar; however, Equistar will be required to indemnify Millennium Petrochemicals for any such claims filed on or after December 1, 2004 related to the assets or businesses contributed by Millennium Petrochemicals to Equistar. Millennium Inorganic Chemicals is one of a number of defendants in 80 premises-based asbestos cases filed in late 2003 in Baltimore County, Maryland. Approximately half of these claims are on the active docket and half are on an inactive docket of claims for which no legal obligations attach and no defense costs are being incurred. With respect to the active docket, at the current rate, cases filed in 2003 are not likely to be scheduled to be tried for at least 10 years. To date, no premises-based asbestos case has been tried in the State of Maryland. Defunct indirect Company subsidiaries are among a number of defendants in 65 premises-based asbestos cases in Texas.

Together with other alleged past manufacturers of lead-based paint and lead pigments for use in paint, the Company, a current subsidiary, as well as alleged predecessor companies, have been named as defendants in various

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 13 – Commitments and Contingencies — (Continued)

legal proceedings alleging that they and other manufacturers are responsible for personal injury, property damage, and remediation costs allegedly associated with the use of these products. The plaintiffs in these legal proceedings include municipalities, counties, school districts, individuals and the State of Rhode Island, and seek recovery under a variety of theories, including negligence, failure to warn, breach of warranty, conspiracy, market share liability, fraud, misrepresentation and public nuisance. Legal proceedings relating to lead pigment or paint are in various procedural stages or pre-trial, post-trial and post-dismissal settings.

The Company’s defense costs to date for lead-based paint and lead pigment litigation largely have been covered by insurance. The Company has not accrued any liabilities for any lead-based paint and lead pigment litigation. The Company has insurance policies that potentially provide approximately $1,000 in indemnity coverage for lead-based paint and lead pigment litigation. That estimate of indemnity coverage would depend upon the timing of any request for indemnity and the solvency of the various insurance carriers that are part of the coverage block at the time of such a request. As a result of insurance coverage litigation initiated by the Company, an Ohio trial court issued a decision in 2002 effectively requiring certain insurance carriers to resume paying defense costs in the lead-based paint and lead pigment cases. Indemnity coverage was not at issue in the Ohio court’s decision. The insurance carriers may appeal the Ohio decision regarding defense costs, and they have in the past and may in the future attempt to deny indemnity coverage if there is ever a settlement or an adverse judgment in any lead-based paint or lead pigment case.

In 1986, a predecessor of a company that is now a subsidiary of the Company sold its recently acquired Glidden Paints business. As part of that sale, the seller agreed to indemnify the purchaser against certain claims made during the first eight years after the sale; the purchaser agreed to indemnify the seller against such claims made after the eight-year period. With the exception of two cases, all pending lead-based paint and lead pigment litigation involving the Company and its subsidiaries, including the Rhode Island case, was filed after the eight-year period. Accordingly, the Company believes that it is entitled to full indemnification from the purchaser against lead-based paint and lead pigment cases filed after the eight-year period. The purchaser disputes that it has such an indemnification obligation, and claims that the seller must indemnify it. Since the Company’s defense costs to date largely have been covered by insurance and there never has been a settlement paid by, nor any judgment rendered against, the Company (or any other company sued in any lead-based paint or lead pigment litigation), the parties’ indemnification claims have not been ruled on by a court.

The Company’s businesses are subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances concerning, among other things, emissions to the air, discharges and releases to land and water, the generation, handling, storage, transportation, treatment and disposal of wastes and other materials and the remediation of environmental pollution caused by releases of wastes and other materials (collectively, “Environmental Laws”). The operation of any chemical manufacturing plant and the distribution of chemical products entail risks under Environmental Laws, many of which provide for substantial fines and criminal sanctions for violations. There can be no assurance that significant costs or liabilities will not be incurred with respect to the Company’s operations and activities. In particular, the production of TiO₂, TiCl₄, VAM, acetic acid, methanol and certain other chemicals involves the handling, manufacture or use of substances or compounds that may be considered to be toxic or hazardous within the meaning of certain Environmental Laws, and certain operations have the potential to cause environmental or other damage. Significant expenditures including facility-related expenditures could be required in connection with any investigation and remediation of threatened or actual pollution, triggers under existing Environmental Laws tied to production or new requirements under Environmental Laws.

The Company cannot predict whether future developments or changes in laws and regulations concerning environmental protection will affect its earnings or cash flow in a materially adverse manner or whether its operating units, Equistar or La Porte Methanol Company will be successful in meeting future demands of regulatory agencies in a manner that will not materially adversely affect the consolidated financial position, results of operations or cash flows of the Company. For example, the eight-county Houston/Galveston region has been designated a severe non-attainment area for ozone by the U.S. Environmental Protection Agency (“EPA”) under a “one-hour” ozone standard. Emission reduction controls for nitrogen oxides (“NOx”), which contribute to ozone formation, must be installed at each of Equistar’s six plants located in the Houston/Galveston region prior to a November 2007 compliance deadline for the one-hour ozone standard. Revised rules adopted by the regulatory agencies changed the required NOx emission reduction levels from 90% to 80%. Under the revised 80% standard, Equistar estimates that

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 13 – Commitments and Contingencies — (Continued)

the incremental capital expenditures would range between $165 and $200. Equistar’s cumulative capital expenditures through March 31, 2004 totaled $80. This estimate could be affected by increased costs for stricter proposed controls over highly reactive, volatile organic compounds (“HRVOCs”). The regulatory agency for the state of Texas, the Texas Commission on Environmental Quality, or “TCEQ,” plans to finalize the HRVOC rules by December 2004. Equistar is still assessing the impact of the proposed HRVOC revisions. In addition, in April 2004, the EPA designated the eight-county Houston/Galveston region a moderate non-attainment area under an “eight-hour” ozone standard. As a result, the TCEQ must submit a plan to the EPA in 2007 to demonstrate compliance with the eight-hour ozone standard in 2010. The TCEQ will continue with its current plan to revise the HRVOC rules in 2004. The timing and amount of the estimated expenditures are subject to these regulatory and other uncertainties, as well as to obtaining the necessary permits and approvals. There can be no assurance as to the ultimate cost of implementing any plan developed to comply with the final ozone standards.

Certain Company subsidiaries have been named as defendants, potentially responsible parties (the “PRPs”), or both, in a number of environmental proceedings associated with waste disposal sites or facilities currently owned, operated or used by the Company’s current or former subsidiaries or predecessors. The Company’s estimated individual exposure for potential cleanup costs, damages for personal injury or property damage related to these proceedings has been estimated to be between $0.01 for several small sites and $67 for the Kalamazoo River Superfund Site in Michigan.

A subsidiary of the Company is named as a PRP at the Kalamazoo River Superfund Site. The site involves cleanup of river sediments and floodplain soils contaminated with polychlorinated biphenyls, cleanup of former paper mill operations and cleanup and closure of landfills associated with former paper mill operations. In October 2000, the Kalamazoo River Study Group (the “KRSG”), of which one of the Company’s subsidiaries is a member, submitted to the State of Michigan a Draft Remedial Investigation and Draft Feasibility Study, which evaluated a number of remedial options for the river. The cost for these remedial options above the amounts accrued could range from $0 to $2,500; however, the Company strongly believes that the likelihood of the cost being $2,500 is remote. At the end of 2001, the EPA took responsibility for the site at the request of the State. Based upon an interim allocation, the Company is paying 55% of costs related to studying and evaluating the environmental condition of the river. The Company’s ultimate liability for the Kalamazoo site will depend on many other factors that have not yet been determined, including the ultimate remedy selected, the number and financial viability of the other members of the KRSG as well as of other PRPs outside the KRSG, and the determination of the final allocation among the members of the KRSG and other PRPs.

On January 16, 2002, Slidell Inc. (“Slidell”) filed a lawsuit against Millennium Inorganic Chemicals Inc., a wholly-owned operating subsidiary of the Company, alleging breach of contract and other related causes of action arising out of a contract between the two parties for the supply of packaging equipment. In the suit, Slidell seeks unspecified monetary damages. The Company believes it has substantial defenses to these allegations and has filed a counterclaim against Slidell.

The Company has accrued $111 as of March 31, 2004 for potential liabilities for environmental and other contingencies, collectively, but which primarily relates to environmental remediation activities. Expenses or benefits associated with these contingencies including changes in estimated costs to resolve these contingencies are included in the Company’s S,D&A costs. Expenses resulting from changes in estimated liabilities for these contingencies for the three months ended March 31, 2004 were $9 and for the three months ended March 31, 2003 were insignificant. The Company expects that cash expenditures related to these potential liabilities will be made over a number of years, and will not be concentrated in any single year.

The Company agreed as part of its Demerger to indemnify Hanson and certain of its subsidiaries against certain of such contractual indemnification obligations, and Millennium Petrochemicals agreed as part of the December 1, 1997 formation of Equistar to indemnify Equistar for certain liabilities related to the assets contributed by Millennium Petrochemicals to Equistar in excess of $7, which threshold was exceeded in 2001. The terms of these indemnification agreements do not limit the maximum potential future payments to the indemnified parties. The maximum amount of future indemnification payments is dependent upon many factors and is not practicable to estimate.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 13 – Commitments and Contingencies — (Continued)

No assurance can be given that actual costs for environmental matters will not exceed accrued amounts or that estimates made with respect to indemnification obligations will be accurate. In addition, it is possible that costs will be incurred with respect to contamination, indemnification obligations or other environmental matters that currently are unknown or as to which it is currently not possible to make an estimate.

Note 14 – Operations by Business Segment

The Company’s principal operations are managed and grouped as three separate business segments: Titanium Dioxide and Related Products, Acetyls and Specialty Chemicals. Operating income and expense not identified with the three separate business segments, including certain of the Company’s S,D&A costs not allocated to its three business segments, employee-related costs from predecessor businesses and certain other expenses, are grouped under the heading Other. The following is a summary of the Company’s operations by business segment:


	Three Months Ended March 31,
	2004			2003
	Restated*			Restated*
Net sales
Titanium Dioxide and Related Products	$	333		$	288
Acetyls		106			102
Specialty Chemicals		26			25

Total	$	465		$	415

Operating income (loss)
Titanium Dioxide and Related Products	$	12		$	21
Acetyls		9			7
Specialty Chemicals		2			2
Other		(13	)		(4	)

Total	$	10		$	26

Depreciation and amortization
Titanium Dioxide and Related Products	$	19		$	22
Acetyls		3			3
Specialty Chemicals		2			2

Total	$	24		$	27

Capital expenditures
Titanium Dioxide and Related Products	$	9		$	7
Acetyls		1			—
Specialty Chemicals		—			1
Other		—			—

Total	$	10		$	8

*	The Company restated its financial statements as disclosed in Notes 17 and 18 to the Consolidated Financial Statements in this Amendment No. 4.

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 14 – Operations by Business Segment — (Continued)


	March 31, 2004		December 31, 2003
Goodwill
Titanium Dioxide and Related Products	$	56	$	56
Acetyls		48		48

Total	$	104	$	104

Note 15 – Information on Equistar

The following is summarized financial information for Equistar:


	March 31, 2004		December 31, 2003
Current assets	$	1,225	$	1,261
Noncurrent assets		3,741		3,767

Total assets	$	4,966	$	5,028

Current liabilities	$	688	$	754
Noncurrent liabilities		2,674		2,673
Partners’ capital		1,604		1,601

Total liabilities and partners’ capital	$	4,966	$	5,028


	Three Months Ended March 31,
	2004		2003
Net sales	$	1,962	$	1,641
Operating income (loss)		61		(96	)
Net income (loss)		5		(146	)

On March 31, 2003, Equistar completed transactions involving a 15-year propylene supply arrangement and the sale of a polypropylene production facility in Pasadena, Texas. Equistar received total cash proceeds of approximately $194, including the value of the polypropylene inventory sold. Approximately $159 of the total cash proceeds represented a partial prepayment for product to be delivered under a long-term supply arrangement, primarily at cost-based prices. Equistar will recognize this deferred revenue over 15 years, as the associated product is delivered.

Note 16 – Supplemental Financial Information

Millennium America, a wholly-owned indirect subsidiary of the Company, is a holding company for all of the Company’s operating subsidiaries other than its operations in the United Kingdom, France, Brazil and Australia. Millennium America is the issuer of the 7% Senior Notes, the 7.625% Senior Debentures, and the 9.25% Senior Notes, and is the principal borrower under the Credit Agreement. Millennium Chemicals is the issuer of the 4% Convertible Senior Debentures. Millennium America fully and unconditionally guarantees all obligations under the Credit Agreement and the 4.00% Convertible Senior Debentures. The 7% Senior Notes, the 7.625% Senior

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 16 – Supplemental Financial Information - Continued

Debentures and the 9.25% Senior Notes, as well as outstanding amounts under the Credit Agreement, are fully and unconditionally guaranteed by Millennium Chemicals. Accordingly, the following Condensed Consolidating Balance Sheets at March 31, 2004 and December 31, 2003, and the Condensed Consolidating Statements of Operations and Cash Flows for each of the three month periods ended March 31, 2004 and 2003, are provided for the Company as supplemental financial information to the Company’s consolidated financial statements to disclose the financial position, results of operations and cash flows of (i) Millennium Chemicals, (ii) Millennium America, and (iii) all subsidiaries of Millennium Chemicals other than Millennium America (the “Non-Guarantor Subsidiaries”). The investment in subsidiaries of Millennium America and Millennium Chemicals are accounted for by the equity method; accordingly, the shareholders’ deficit of Millennium America and Millennium Chemicals are presented as if each of those companies and their respective subsidiaries were reported on a consolidated basis.


Condensed Consolidating Balance Sheets	Millennium America Inc.			Millennium Chemicals Inc.			Non-Guarantor Subsidiaries		Eliminations			Millennium Chemicals Inc. and Subsidiaries
March 31, 2004
(Restated – See Notes 17 and 18)
ASSETS
Inventories	$	—		$	—		$	417	$	—		$	417
Other current assets		80			1			515		—			596
Property, plant and equipment, net		—			—			753		—			753
Investment in Equistar		—			—			471		—			471
Investment in subsidiaries		319			66			—		(385	)		—
Other assets		15			3			36		—			54
Goodwill		—			—			104		—			104
Due from parent and affiliates, net		655			—			—		(655	)		—

Total assets	$	1,069		$	70		$	2,296	$	(1,040	)	$	2,395

LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current maturities of long-term debt	$	—		$	—		$	5	$	—		$	5
Other current liabilities		34			8			375		—			417
Long-term debt		1,245			150			14		—			1,409
Deferred income taxes		—			—			253		—			253
Other liabilities		—			—			373		—			373
Due to parent and affiliates, net		—			2			653		(655	)		—

Total liabilities		1,279			160			1,673		(655	)		2,457
Minority interest		—			—			28		—			28
Shareholders’ (deficit) equity		(210	)		(90	)		595		(385	)		(90	)

Total liabilities and shareholders’ (deficit) equity	$	1,069		$	70		$	2,296	$	(1,040	)	$	2,395

December 31, 2003
(Restated – See Notes 17 and 18)
ASSETS
Inventories	$	—		$	—		$	457	$	—		$	457
Other current assets		24			1			526		—			551
Property, plant and equipment, net		—			—			766		—			766
Investment in Equistar		—			—			469		—			469
Investment in subsidiaries		336			62			—		(398	)		—
Other assets		12			3			36		—			51
Goodwill		—			—			104		—			104
Due from parent and affiliates, net		733			—			—		(733	)		—

Total assets	$	1,105		$	66		$	2,358	$	(1,131	)	$	2,398

LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current maturities of long-term debt	$	—		$	—		$	6	$	—		$	6
Other current liabilities		9			1			357		—			367
Long-term debt		1,295			150			16		—			1,461
Deferred income taxes		—			—			257		—			257
Other liabilities		—			—			371		—			371
Due to parent and affiliates, net		—			6			727		(733	)		—

Total liabilities		1,304			157			1,734		(733	)		2,462
Minority interest		—			—			27		—			27
Shareholders’ (deficit) equity		(199	)		(91	)		597		(398	)		(91	)

Total liabilities and shareholders’ (deficit) equity	$	1,105		$	66		$	2,358	$	(1,131	)	$	2,398

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 16 – Supplemental Financial Information - Continued


Condensed Consolidating Statements of Operations	Millennium America Inc.			Millennium Chemicals Inc.			Non-Guarantor Subsidiaries			Eliminations		Millennium Chemicals Inc. and Subsidiaries
Three Months Ended March 31, 2004
(Restated – See Notes 17 and 18)
Net sales	$	—		$	—		$	465		$	—	$	465
Cost of products sold		—			—			388			—		388
Depreciation and amortization		—			—			24			—		24
Selling, development and administrative expense		—			—			36			—		36
Asset impairment charges		—			—			3			—		3
Combination costs		—			—			3			—		3
Reorganization and office closure costs		—			—			1			—		1

Operating income		—			—			10			—		10
Interest expense, net		(23	)		(2	)		—			—		(25	)
Intercompany interest income (expense), net		25			—			(25	)		—		—
Earnings on Equistar investment		—			—			2			—		2
Equity in loss of subsidiaries		(14	)		(11	)		—			25		—
Other expense, net		—			—			(2	)		—		(2	)
(Provision for) benefit from income taxes		(1	)		1			3			—		3

Net loss	$	(13	)	$	(12	)	$	(12	)	$	25	$	(12	)

Three Months Ended March 31, 2003
(Restated – See Notes 17 and 18)
Net sales	$	—		$	—		$	415		$	—	$	415
Cost of products sold		—			—			331			—		331
Depreciation and amortization		—			—			27			—		27
Selling, development and administrative expense		—			—			31			—		31

Operating income		—			—			26			—		26
Interest expense, net		(22	)		—			—			—		(22	)
Intercompany interest income (expense), net		24			(1	)		(23	)		—		—
Loss on Equistar investment		—			—			(43	)		—		(43	)
Equity in loss of subsidiaries		(42	)		(26	)		—			68		—
Other expense, net		—			—			(3	)		—		(3	)
(Provision for) benefit from income taxes		(1	)		—			16			—		15
Cumulative effect of accounting change		1			(1	)		(1	)		—		(1	)

Net loss	$	(40	)	$	(28	)	$	(28	)	$	68	$	(28	)

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 16 – Supplemental Financial Information - Continued


Condensed Consolidating Statements of Cash Flows	Millennium America Inc.			Millennium Chemicals Inc.			Non-Guarantor Subsidiaries			Eliminations		Millennium Chemicals Inc. and Subsidiaries
Three Months Ended March 31, 2004
(Restated - See Notes 17 and 18)
Cash flows from operating activities	$	22		$	(1	)	$	17		$	—	$	38

Cash flows from investing activities
Capital expenditures		—			—			(10	)		—		(10	)

Cash used in investing activities		—			—			(10	)		—		(10	)

Cash flows from financing activities
Proceeds from long-term debt		16			—			—			—		16
Repayment of long-term debt		(68	)		—			(2	)		—		(70	)
Intercompany		85			(8	)		(77	)		—		—
Increase in notes payable and other short-term borrowings		—			6			(1	)		—		5
Proceeds from exercise of stock options		—			3			—			—		3

Cash provided by (used in) financing activities		33			1			(80	)		—		(46	)

Effect of exchange rate changes on cash		—			—			5			—		5

Increase (decrease) in cash and cash equivalents		55			—			(68	)		—		(13	)
Cash and cash equivalents at beginning of year		20			—			189			—		209

Cash and cash equivalents at end of period	$	75		$	—		$	121		$	—	$	196

Three Months Ended March 31, 2003
(Restated - See Notes 17 and 18)
Cash flows from operating activities	$	25		$	(1	)	$	(38	)	$	—	$	(14	)

Cash flows from investing activities
Capital expenditures		—			—			(8	)		—		(8	)

Cash used in investing activities		—			—			(8	)		—		(8	)

Cash flows from financing activities
Dividends to shareholders		—			(9	)		—			—		(9	)
Proceeds from long-term debt		95			—			1			—		96
Repayment of long-term debt		(61	)		—			(5	)		—		(66	)
Intercompany		(64	)		10			54			—		—
Increase in notes payable		—			—			(1	)		—		(1	)

Cash (used in) provided by financing activities		(30	)		1			49			—		20

Effect of exchange rate changes on cash		—			—			2			—		2

(Decrease) increase in cash and cash equivalents		(5	)		—			5			—		—
Cash and cash equivalents at beginning of year		6			—			119			—		125

Cash and cash equivalents at end of period	$	1		$	—		$	124		$	—	$	125

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) — (Continued)

(Dollars in millions, except share data)

Note 17 – Restatement of Financial Statements – August 2004

In August 2004, the Company restated its Consolidated Balance Sheet and Statement of Shareholders’ Equity at December 31, 2003 and March 31, 2004 to correct errors in the computation of deferred income taxes relating to the Company’s investment in Equistar (the “August 2004 Restatement”). The August 2004 Restatement decreased the Company’s liability for deferred income taxes and Shareholders’ deficit at December 31, 2003 and March 31, 2004 by $15. The August 2004 Restatement did not affect the Company’s cash flow or operating income for any period.

A summary of the aggregate effect of the August 2004 Restatement on the Company’s Consolidated Balance Sheets for the periods presented herein is shown below. The Company’s December 31, 2003 restated financial statements are included in Amendment No. 2 to its Annual Report on Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission on August 9, 2004.


	As of March 31, 2004						As of December 31, 2003
	As Reported			As Restated			As Reported			As Restated
Changes to Consolidated Balance Sheets:
Deferred income taxes	$	284		$	269		$	287		$	272
Total liabilities		2,437			2,422			2,444			2,429
Accumulated deficit		(987	)		(972	)		(977	)		(962	)
Total shareholders’ deficit		(70	)		(55	)		(73	)		(58	)

Note 18 – Restatement of Financial Statements – February 2005

In February 2005, the Company restated its financial statements for the three months ended March 31, 2004 to correct errors made in recording estimated liabilities for future environmental remediation spending associated with existing obligations, primarily related to the Kalamazoo River Superfund Site, that were not recorded previously (the “February 2005 Restatement”). As a result of the February 2005 Restatement, the Company’s consolidated balance sheet as of March 31, 2004 reflects increases in Other liabilities and Accumulated deficit of $49 and $33, respectively, and a decrease in Deferred tax liabilities of $16. Similarly, the consolidated balance sheet as of December 31, 2003 reflects increases in Other liabilities and Accumulated deficit of $46 and $31, respectively, and a decrease in Deferred tax liabilities of $15. The Company’s consolidated statement of operations reflects an increase in S,D&A expense of $3 and $1, respectively, for the three-month periods ended March 31, 2004 and 2003, and an increase of $1 in Benefit from income taxes for the three-month period ended March 31, 2004. The Company also has made certain adjustments to the financial statements for the periods presented that previously had been considered immaterial to those financial statements, to correct the accrual for vacations earned and to correctly present the effect of bank overdrafts on cash flows as a financing activity. These adjustments, which had no effect on results of operations in the periods presented, increased cash provided by operations and decreased financing cash flows by $1 for the three month period ended March 31, 2004, and increased Accumulated deficit and Accrued expenses and other liabilities by $2 for each period presented.

The table below summarizes the aggregate effect of the February 2005 Restatement on the Company’s Consolidated Balance Sheet, Consolidated Statement of Operations and Consolidated Statement of Cash Flows of operations for the periods presented herein.


	For the Three Month Period Ended March 31,
	2004						2003
	As Reported			As Restated			As Reported			As Restated
Changes to Consolidated Statement of Operations:
Selling, development and administrative expense	$	33		$	36		$	30		$	31
Operating income		13			10			27			26
Loss before income taxes and minority interest and cumulative effect of accounting change		(11	)		(14	)		(38	)		(39	)
Benefit from income taxes		2			3			15			15
Loss before minority interest and cumulative effect of accounting change		(9	)		(11	)		(23	)		(24	)
Loss before cumulative effect of accounting change		(10	)		(12	)		(26	)		(27	)
Net loss		(10	)		(12	)		(27	)		(28	)
Basic and diluted loss per share:
Before cumulative effect of accounting change		(0.16	)		(0.19	)		(0.41	)		(0.42	)
After cumulative effect of accounting change		(0.16	)		(0.19	)		(0.43	)		(0.44	)

	As of March 31, 2004						As of December 31, 2003
	As Reported			As Restated			As Reported			As Restated

Changes to Consolidated Balance Sheets:
Accrued expeses and other liabilities	$	146		$	148		$	124		$	126
Deferred income taxes		269			253			272			257
Other liabilities		324			373			325			371
Total liabilities		2,422			2,457			2,429			2,462
Accumulated deficit		(972	)		(1,007	)		(962	)		(995	)
Total shareholders’ deficit		(55	)		(90	)		(58	)		(91	)

	For the Three Month Period Ended March 31,
	2004						2003
	As Reported			As Restated			As Reported			As Restated

Changes to Consolidated Statements of Cash Flows:
Net loss	$	(10	)	$	(12	)	$	(27	)	$	(28	)
Deferred income tax benefit		(5	)		(6	)		(21	)		(21	)
Increase in accrued expenses and other liabilities and income taxes payable		26			27			4			4
Decrease in other liabilities		(5	)		(2	)		(12	)		(11	)
Cash provided by (used in) operating activities		37			38			(14	)		(14	)
Increase (decrease) in notes payable and other short-term borrowings		6			5			(1	)		(1	)
Cash (used in) provided by financing activites		(45	)		(46	)		20			20

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

In August 2004, Millennium Chemicals Inc. (the “Company”) restated its Consolidated Balance Sheet and Statement of Shareholders’ Equity at December 31, 2003 (the “August 2004 Restatement”) to correct errors in the computation of deferred income taxes relating to the Company’s investment in Equistar. The August 2004 Restatement decreased the Company’s liability for deferred income taxes at December 31, 2003 and decreased Accumulated deficit by $15 million. The Company’s December 31, 2003 restated financial statements reflecting the August 2004 Restatement were included in Amendment No. 2 to its Annual Report on Form 10-K/A for the year ended December 31, 2003 filed with the Securities and Exchange Commission on August 9, 2004.

In addition to the August 2004 Restatement described above, the Company restated its Consolidated Balance Sheet at December 31, 2003, March 31, 2004, June 30, 2004 and September 30, 2004, and its Statement of Operations for the periods then ended to correct errors made in recording estimated liabilities for future environmental remediation spending associated with existing obligations, primarily related to the Kalamazoo River Superfund Site, that were not recorded previously (the “February 2005 Restatement”). The February 2005 Restatement increased environmental remediation liabilities by $46 million, decreased deferred tax liabilities by $15 million and increased shareholders’ deficit by $31 million as of December 31, 2003. The February 2005 Restatement similarly increased environmental remediation liabilities by $49 million, decreased deferred tax liabilities by $16 million and increased Shareholders’ deficit by $33 million at March 31, 2004. On February 14, 2005, the Company filed Amendment No. 5 to its Annual Report on Form 10-K/A with the Securities and Exchange Commission to restate its financial statements for the year ended December 31, 2003.

This Amendment No. 4 includes restated financial statements reflecting the February 2005 Restatement. For additional information including the effect of the February 2005 Restatement on each period presented, see Note 18 to the Consolidated Financial Statements.

Disclosure Concerning Forward-Looking Statements

The statements in this Amendment No. 4 that are not historical facts are, or may be deemed to be, “forward-looking statements” (“Cautionary Statements”) as defined in the Private Securities Litigation Reform Act of 1995. Some of these statements can be identified by the use of forward-looking terminology such as “prospects,” “outlook,” “believes,” “estimates,” “intends,” “may,” “will,” “should,” “anticipates,” “expects” or “plans,” or the negative or other variation of these or similar words, or by discussion of trends and conditions, strategy or risks and uncertainties. In addition, from time to time, Millennium Chemicals Inc. and its majority-owned subsidiaries (“the Company”) or its representatives have made or may make forward-looking statements in other filings that the Company makes with the Securities and Exchange Commission, in press releases or in oral statements made by or with the approval of one of its authorized executive officers.

These forward-looking statements are only present expectations as at May 14, 2004, the date the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 was originally filed with the Securities and Exchange Commission. Actual events or results may differ materially. Factors that could cause such a difference include:

•

the ability of the Company to complete its proposed business combination with Lyondell Chemical Company (“Lyondell”), as described in more detail in “Agreement for a Stock-for-Stock Business Combination” below;

•

the cyclicality and volatility of the chemical industries in which the Company and Equistar Chemicals, LP (“Equistar”) operate, particularly fluctuations in the demand for ethylene, its derivatives and acetyls and the sensitivity of these industries to capacity additions;

•

general economic conditions in the geographic regions where the Company and Equistar generate sales, and the impact of government regulation and other external factors, in particular, the events in the Middle East;

•

the ability of Equistar to distribute cash to its partners and uncertainties arising from the Company’s shared control of Equistar and the Company’s contractual commitments regarding possible future capital contributions to Equistar;

•

changes in the cost of energy and raw materials, particularly natural gas and ethylene, and the ability of the Company and Equistar to pass on cost increases to their customers;

•

the ability of raw material suppliers to fulfill their commitments;

•

the ability of the Company and Equistar to achieve their productivity improvement, cost reduction and working capital targets, and the occurrence of operating problems at manufacturing facilities of the Company or Equistar;

•

risks of doing business outside the United States, including currency fluctuations;

•

the cost of compliance with the extensive environmental regulations affecting the chemical industry and exposure to liabilities for environmental remediation and other environmental matters relating to the Company’s and Equistar’s current and former operations;

•

pricing and other competitive pressures;

•

legal proceedings relating to present and former operations (including proceedings based on alleged exposure to lead-based paints and lead pigments, asbestos and other materials), ongoing or future tax audits, and other claims; and

•

the Company’s substantial indebtedness and its impact on the Company’s cash flow, business operations and ability to obtain additional financing;

A further description of these risks, uncertainties and other matters can be found in Exhibit 99.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2004, as initially filed with the Securities and Exchange Commission.

Some of these Cautionary Statements are discussed in more detail in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report. Readers are cautioned not to place undue reliance on forward-looking or Cautionary Statements, which reflect present expectations as at May 14, 2004, the date the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 was originally filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking or Cautionary Statement. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by the Cautionary Statements in this Quarterly Report and by any additional Cautionary Statements provided with such subsequent written and oral forward-looking statements. Readers are advised to consult any further disclosures the Company may make on related subjects in subsequent 10-Q, 8-K and 10-K reports, including amendments thereto, to the Securities and Exchange Commission.

Agreement for a Stock-for-Stock Business Combination

The transaction is subject to customary conditions, including approval by both companies’ shareholders and receipt of required regulatory approvals and amendments to each of Lyondell’s and the Company’s credit agreements and Lyondell’s receivables sales facility. The transaction is expected to close in the third quarter of 2004. The transaction involves the merger of Millennium Subsidiary LLC, a newly created subsidiary of the Company, into the Company, in which the Company’s common stock now held by its public shareholders will be converted into common stock of Lyondell, and the Company’s preferred stock to be issued to Lyondell immediately before the merger will be converted into common stock of the surviving entity. As a result, the Company will become a wholly-owned subsidiary of Lyondell. After the close of the transaction, the combined company will be called “Lyondell Chemical Company”

and will be headquartered in Houston, Texas. Dan F. Smith, Lyondell’s current President and Chief Executive Officer, and Dr. William T. Butler, Lyondell’s Chairman of the Board of Directors, will each continue in their respective roles. Two independent members of the Company’s current Board will join the Lyondell Board, effective at the time of the closing.

In addition, in connection with the proposed transaction Lyondell and the Company have filed relevant materials with the Securities and Exchange Commission, including Lyondell’s registration statement containing a preliminary joint proxy statement/prospectus, which was filed on April 26, 2004. The definitive joint proxy statement/prospectus will be sent to holders of Lyondell’s and the Company’s common stock when it becomes available. Investors and security holders are urged to read the preliminary joint proxy statement/prospectus on file with the Securities and Exchange Commission, the definitive joint proxy statement/prospectus when it becomes available and any other relevant documents filed by Lyondell or the Company because they contain, or will contain, important information. Investors and security holders may obtain a free copy of the preliminary joint proxy statement/prospectus and the definitive joint proxy statement/prospectus (when it becomes available) and other documents filed by Lyondell and the Company with the Securities and Exchange Commission for free at the Securities and Exchange Commission’s website at www.sec.gov. The preliminary joint proxy statement/prospectus and the definitive joint proxy statement/prospectus (when it becomes available) and the other documents filed by the Company may be obtained free from the Company by calling the Company’s Investor Relations Department at (410) 229-8113. The preliminary joint proxy statement/prospectus and the definitive joint proxy statement/prospectus (when it becomes available) and the other documents filed by Lyondell may also be obtained free from Lyondell by calling Lyondell’s Investor Relations Department at (713) 309-4590.

For additional information relating to the proposed transaction, including risk factors, please refer to the preliminary joint proxy statement/prospectus and the definitive joint proxy statement/prospectus (when it becomes available).

The respective executive officers and directors of Lyondell and the Company and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Lyondell’s executive officers and directors is available in its proxy statement filed with the Securities and Exchange Commission by Lyondell on March 16, 2004, and information regarding the Company’s directors and executive officers is available in its Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission on April 27, 2004. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the Securities and Exchange Commission.

For the three months ended March 31, 2004, the Company has incurred approximately $3 million of professional services costs in connection with the proposed combination, which are included in Combination costs in the accompanying unaudited Consolidated Statements of Operations.

Cost Reduction Program; Suspension of Dividend

The Company expects to realize approximately $20 million of annual operating expense savings from the cost reduction program announced on July 21, 2003. The Company has recorded cumulative charges related to the program of $19 million (including $1 million for the three months ended March 31, 2004), of which $18 million was for severance-related costs and $1 million was for contractual commitments for ongoing lease costs, net of expected sublease income, associated with the closure of the Red Bank, New Jersey office for the remaining term of the lease agreement. Cumulative severance-related cash payments of $22 million for the implementation of this program were made through March 31, 2004, including $8 million in the first quarter of 2004. Substantially all of the remainder of the cash payments relating to this program, which are estimated to be approximately $4 million, will be disbursed during the next several quarters. No significant charges associated with this program are expected in future periods. The cumulative charges of $19 million associated with the cost reduction program are less than the cumulative severance-related cash payments of $22 million because some of the cash payments made under the program, primarily for

retirement benefits, were related to expenses and liabilities that were recorded through the normal course of business in periods prior to the implementation of this program in mid-2003.

Operating Results

The Company’s principal operations are grouped into three business segments: Titanium Dioxide and Related Products, Acetyls, and Specialty Chemicals. Operating income and expense not identified with the three separate business segments, including certain of the Company’s selling, development and administrative (“S,D&A”) costs not allocated to its three business segments, employee-related costs from predecessor businesses and certain other expenses, are grouped under the heading Other. The Company also holds a 29.5% interest in Equistar, which is accounted for using the equity method (see Note 1 to the unaudited Consolidated Financial Statements included in this Quarterly Report.) A discussion of Equistar’s financial results for the relevant period is included below, as the Company’s interest in Equistar represents a significant component of the Company’s assets and Equistar’s results can have a significant effect on the Company’s consolidated results of operations.

The following information should be read in conjunction with the Company’s Consolidated Financial Statements and Notes thereto and the discussion included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2003, as amended by Amendment No. 5 on Form 10-K/A filed with the Securities and Exchange Commission on February 14, 2005.

Results of Consolidated Operations


	Three Months Ended March 31,
	2004			2003
	(Millions, except share data)
	Restated*			Restated*
Net sales	$	465		$	415
Operating income		10			26
Earnings (loss) on Equistar investment		2			(43	)
Loss before cumulative effect of accounting change		(12	)		(27	)
Net loss		(12	)		(28	)
Basic and diluted loss per share:
Before cumulative effect of accounting change		(0.19	)		(0.42	)
After cumulative effect of accounting change		(0.19	)		(0.44	)

*	The Company restated its financial statements as disclosed in Notes 17 and 18 to the Consolidated Financial Statements included in this Amendment No. 4.

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

The Company’s net loss was $12 million, or $0.19 per share, for the three months ended March 31, 2004 and $28 million, or $0.44 per share, for the corresponding period in 2003. In the first quarter of 2003, the Company reported a charge of $1 million or $0.02 per share for the cumulative effect of an accounting change for the adoption of Statement of Financial Accounting Standards (“SFAS”) No. 143, “Accounting for Asset Retirement Obligations”, due to required changes in the method for recognizing asset retirement obligations. The Company’s pre-tax loss decreased by $25 million in the first quarter of 2004 compared to the corresponding period in 2003, primarily due to a $45 million improvement in earnings (loss) from the Company’s investment in Equistar, partially offset by a $16 million decrease in operating income and a $3 million increase in net interest expense.

The Company’s operating income in the first quarter of 2004 of $10 million decreased $16 million, from $26 million in the first quarter of 2003, due to a decrease in operating income of $9 million in the Titanium Dioxide and Related Products business segment and an increase of $9 million in Other operating loss not identified with the three separate business segments, partially offset by a $2 million increase in operating income in the Acetyls business

segment. Operating income in the Specialty Chemicals business segment for the first quarter of 2004 was consistent with the corresponding period in the prior year.

Net sales of $465 million in the first quarter of 2004 increased by $50 million, or 12%, from the same period in the prior year primarily due to higher sales volume in all three of the Company’s business segments, particularly the Titanium Dioxide and Related Products business segment, and foreign currency strength against the US dollar in the Titanium Dioxide and Related Products and Acetyls business segments.

Manufacturing and other costs of sales were generally higher in the first quarter of 2004 compared to the corresponding quarter of the prior year primarily due to the unfavorable effect of translating local currency manufacturing costs into a weaker US dollar, partially offset by higher fixed cost absorption due to higher plant operating rates, particularly in the Titanium Dioxide and Related Products business segment. Despite lower natural gas costs in the first quarter of 2004, manufacturing and other costs of sales in the Acetyls business segment were higher compared to the first quarter of 2003 primarily due to higher ethylene costs and higher inventory costs carried into the first quarter of 2004.

S,D&A costs of $36 million in the first quarter of 2004 increased by $5 million from the first quarter of 2003 due to a net increase in expenses not identified with the three separate business segments, including expenses of $9 million in the first quarter of 2004 resulting from changes in estimated liabilities for legal and environmental contingencies related to predecessor businesses. Certain S,D&A costs are lower as the result of the Company’s cost reduction program announced in July 2003 (see “Cost Reduction Program; Suspension of Dividend” above); however, certain other S,D&A costs are higher, including pension costs.

Asset impairment charges in the first quarter of 2004 of $3 million represented expenditures for property, plant and equipment at the Company’s Le Havre, France titanium dioxide (“TiO₂”) manufacturing plant. In the fourth quarter of 2003, the carrying value of the property, plant and equipment at the Le Havre manufacturing plant was determined to be impaired, and a charge was required to write down the basis in those assets to zero. Capital expenditures at this plant for the three months ended March 31, 2004 were capitalized as property, plant and equipment and then immediately written off as asset impairment charges as a result of evaluating those assets for impairment under the guidance of SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS No. 144”). Since the basis of all of the property, plant and equipment for this plant has been written down to zero, no depreciation expense for this plant is recorded in manufacturing and other costs of sales.

Combination costs in the first quarter of 2004 of $3 million represented professional services costs incurred in connection with the proposed stock-for-stock business combination announced on March 29, 2004 that, if completed, will result in the acquisition of the Company by Lyondell (see “Agreement for a Stock-for-Stock Business Combination” above).

The Company reported pre-tax earnings from its investment in Equistar of $2 million for the three months ended March 31, 2004, an improvement of $45 million compared to the pre-tax loss of $43 million for the three months ended March 31, 2003. The loss in the first quarter of 2003 included the Company’s share of a loss on the sale of a polypropylene production facility of $4 million. The increase in Equistar’s results for the first quarter of 2004 compared to the same period of 2003 is primarily due to higher product margins as a result of higher sales prices, especially for co-products propylene and benzene, which increased more than increases in the costs of raw materials. In addition, the first quarter of 2004 benefited from 5% higher ethylene and derivative sales volume. The improving economic conditions and tight supply and demand balances in several of Equistar’s products contributed to improved operating results at Equistar during the first quarter of 2004 compared to the first quarter of 2003. Despite first quarter 2004 crude oil prices that exceeded those experienced during the first quarter of 2003, the economics of ethylene production from Equistar’s liquid-based crackers improved compared to the first quarter of 2003. This was due to the significantly higher co-product sales prices in the first quarter of 2004 that more than offset the impact of the higher crude oil prices.

Outlook for 2004

The Company expects seasonally higher TiO₂ sales volume and improved TiO₂ average selling prices in local currencies in the second quarter of 2004 compared to the first quarter of 2004 in the Titanium Dioxide and Related Products business segment. The Company expects to realize higher selling prices as a result of implementing previous price announcements. Lower production volume is expected in the second quarter of 2004 due to the scheduling of planned maintenance activities.

In the second quarter of 2004, sales volume for the Acetyls business segment is expected to be similar to the first quarter of 2004 and average selling prices in local currency are expected to be slightly higher. In the second quarter of 2004, scheduled maintenance shutdowns will reduce production volume. Additionally, quarter-to-date prices paid and future prices indicate higher costs in the second quarter of 2004 for natural gas, Acetyls’ primary raw material. These higher costs may compress margins.

In the second quarter of 2004, business conditions in the Specialty Chemicals business segment are expected to be similar to the first quarter of 2004.

Improving industry conditions have enabled Equistar to deal with continuing high and volatile raw material and energy prices more successfully than at any other time in the past three years. Although it may be premature to say that the economy and the chemical industry have entered a sustained strong upturn, with continued solid global economic growth and some stabilization of energy prices, Equistar could benefit from improvement in both demand and product margins during the course of 2004. Equistar’s sales volume for key products has improved thus far in the second quarter of 2004. Equistar completed a major maintenance turnaround in the second quarter of 2004, which will have some effect on the quarter’s operating results.

Segment Analysis

Titanium Dioxide and Related Products

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

Operating income in the Titanium Dioxide and Related Products business segment for the first quarter of 2004 was $12 million, a decrease of $9 million, or 43%, compared to the corresponding quarter of 2003 as higher sales volume ($7 million) and higher selling prices ($1 million) were more than offset by higher manufacturing and other costs of sales ($13 million) and higher S,D&A expenses ($1 million). Additionally, operating income for the first quarter of 2004 included asset impairment charges of $3 million, which represented the write off of expenditures for property, plant and equipment at the Company’s Le Havre, France manufacturing plant. In the fourth quarter of 2003, the carrying value of the property, plant and equipment at the Le Havre manufacturing plant was determined to be impaired, and a charge was required to write down the basis in those assets to zero. Capital expenditures at this plant for the three months ended March 31, 2004 were capitalized as property, plant and equipment and then immediately written off as asset impairment charges as a result of evaluating those assets for impairment under the guidance of SFAS No. 144. Since the basis of all the property, plant and equipment for this plant has been written down to zero, no depreciation expense for this plant is recorded in manufacturing and other costs of sales.

Sales revenue in the first quarter of 2004 of $333 million increased by $45 million, or 16%, compared to the prior year quarter primarily due to higher sales volume and the favorable effect of translating sales denominated in stronger foreign currencies into US dollars. TiO₂ sales volume in the first quarter of 2004 was 15% higher than the prior year quarter, with increases reported in all major geographic regions globally except Central and South America. Overall, the Company estimates that the global TiO₂ market increased approximately 3% to 5% compared to the first quarter of the prior year due to improved global economic conditions. The Company’s average TiO₂ selling price for the first quarter of 2004 in local currencies was 7% lower than the first quarter of the prior year, but was similar to the prior year quarter in US dollar terms.

Manufacturing and other costs of sales in the first quarter of 2004 were higher than the corresponding quarter of 2003 due to the unfavorable effect of translating manufacturing costs incurred in stronger foreign currencies into US dollars, partially offset by higher fixed cost absorption due to increased production volume, lower depreciation expense due to the writedown of assets at the Le Havre manufacturing plant, and lower energy and raw material costs. The overall operating rate of the Company’s TiO₂ plants was 93% in the first quarter of 2004 compared to 88% in the same period of 2003. The increase in operating rates was due to strong operating performance across the operating facilities in response to increased demand.

S,D&A expenses in the first quarter of 2004 increased by $1 million or 5% compared to the prior year quarter.

Acetyls

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

Operating income in the Acetyls business segment of $9 million for the three months ended March 31, 2004 increased by $2 million, or 29%, compared to operating income of $7 million in the first quarter of 2003 primarily due to higher average selling prices ($3 million) and higher sales volume ($1 million), partially offset by higher manufacturing and other costs of sales ($2 million). Net sales for the first quarter of 2004 of $106 million increased by $4 million, or 4%, from the prior year quarter primarily due to slightly higher average selling prices. The aggregate weighted-average selling price in US dollars for vinyl acetate monomer (“VAM”) and acetic acid increased by 4% from the first quarter of 2003 primarily due to the favorable effect of translating sales denominated in stronger foreign currencies into US dollars. Aggregate sales volume for VAM and acetic acid for the first quarter of 2004 was 8% higher than the first quarter of 2003.

Manufacturing and other costs of sales for VAM and acetic acid in the first quarter of 2004 were higher than the first quarter of 2003, despite lower natural gas costs in the first quarter of 2004, primarily due to higher ethylene costs and higher-cost inventory carried into the first quarter of 2004 compared to the first quarter of 2003 due to higher average feedstock costs in December 2003, particularly natural gas and ethylene.

S,D&A expenses in the first quarter of 2004 were similar to S,D&A expenses in the same period of 2003.

Specialty Chemicals

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

Operating income in the Specialty Chemicals business segment for the three months ended March 31, 2004 of $2 million was similar to operating income for the three months ended March 31, 2003. Lower average selling prices in the first quarter of 2004 were offset by lower S,D&A costs.

Net sales for the three months ended March 31, 2004 of $26 million increased by $1 million, or 4%, compared to the three months ended March 31, 2003. Sales volume in the first quarter of 2004 was 8% higher than the first quarter of 2003 as sales volume increased across most product lines. However, the weighted average selling price for Specialty Chemicals products decreased by 4% from the first quarter of 2003. The combination of competitive pricing and proportionally higher sales volume in lower-priced product lines contributed to the decrease in average selling prices in the first quarter of 2004 compared to the same period of 2003.

Manufacturing and other costs of sales in the first quarter of 2004 were similar to the first quarter of 2003. The average cost of crude sulfate turpentine (“CST”), the principal raw material used in the business, and costs for raw materials other than CST were higher in the first quarter of 2004 than in the prior year quarter. However, the increase in manufacturing costs per unit was offset by lower distribution costs per unit.

S,D&A costs for the three months ended March 31, 2004 were $1 million, or 33%, lower than the same period of 2003.

Other


	Three Months Ended March 31,
	2004			2003
	(Millions)
	Restated*			Restated*
Operating loss	$	(13	)	$	(4	)

*	The Company restated its financial statements as disclosed in Notes 17 and 18 to the Consolidated Financial Statements included in this Amendment No. 4.

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

Operating loss not identified with the three separate business segments for the three months ended March 31, 2004 was $9 million higher than the three months ended March 31, 2003 primarily due to expenses of $9 million in the first quarter of 2004 resulting from changes in estimated liabilities for legal and environmental contingencies related to predecessor businesses, $3 million of professional services costs incurred in connection with the proposed stock-for-stock business combination announced on March 29, 2004 that, if completed, will result in the acquisition of the Company by Lyondell (see “Agreement for a Stock-for-Stock Business Combination” above), and $1 million of reorganization and office closure charges associated with the Company’s cost reduction program announced in July 2003, partially offset by $1 million higher income from employee benefit plans related to predecessor businesses and a $2 million reduction in other expenses not allocated to the separate business segments.

Equistar


	Three Months Ended March 31,
	2004		2003
	(Millions)
Income (loss), as reported by Equistar	$	5	$	(146	)

Earnings (loss) on Equistar investment, as reported by the Company	$	2	$	(43	)

Three Months Ended March 31, 2004 Compared to the Three Months Ended March 31, 2003

The Company reported pre-tax earnings from its investment in Equistar of $2 million for the three months ended March 31, 2004, an increase of $45 million compared to the pre-tax loss of $43 million for the three months ended March 31, 2003.

Equistar reported net income of $5 million in the first quarter of 2004 compared to a net loss of $146 million in the first quarter of 2003. Equistar’s loss in the first quarter of 2003 included a $12 million loss on the sale of a polypropylene production facility. The remaining increase in Equistar’s results in the first quarter of 2004 compared to the corresponding period in the prior year is primarily due to higher product margins as a result of higher sales prices, especially for co-products propylene and benzene, which increased more than increases in the costs of raw materials. In the first quarter 2004, ethylene producers experienced significantly higher prices for co-products such as propylene and benzene, contributing to a lower net cost of ethylene production for producers using liquid raw materials, which yield a higher ratio of co-products. Supply and demand fundamentals have also improved as evidenced by higher operating rates for ethylene producers.

Equistar’s Petrochemicals segment reported operating income of $104 million for the first quarter of 2004, an increase of $136 million compared to an operating loss of $32 million in the first quarter of the prior year. The increase in operating income was primarily due to higher product margins. Revenues for Equistar’s Petrochemicals segment increased 21% in the first quarter of 2004 compared to the corresponding period in the prior year due to higher sales prices and an 8% increase in sales volume. Benchmark ethylene sales prices averaged 11% higher in the first quarter of 2004 compared to the first quarter of 2003, while benchmark propylene sales prices averaged 21% higher. Costs of sales increased 13% due to the higher sales volume and an increase in the cost of crude oil-based liquid raw materials, which increased due to a 3% increase in the cost of crude oil. Equistar also used a higher proportion of liquid raw materials in the first quarter of 2004 as a result of the timing of scheduled maintenance turnarounds of liquids-based ethylene plants in the first quarter of 2004 relative to the first quarter of 2003, which also contributed to higher sales of co-products, such as propylene.

Equistar’s Polymers segment reported an operating loss of $14 million compared to an operating loss of $35 million in the first quarter 2003. The operating loss in the first quarter of 2003 included a $12 million loss on the sale of a polypropylene production facility in Pasadena, Texas. The remaining improvement in results in the first quarter of 2004 compared to the first quarter of 2003 was primarily due to higher product margins as sales prices increased more than raw material costs. Revenues in Equistar’s Polymers segment in the first quarter of 2004 increased 9% due to higher average sales prices, which increased in response to higher raw material costs. While sales volume in both periods were comparable, first quarter 2003 sales volume included approximately 85 million pounds of sales related to the Pasadena, Texas polypropylene plant, which was sold on March 31, 2003. On a comparable basis, sales volume increased 7% in the first quarter of 2004 compared to the first quarter of 2003. Costs of sales increased 7% in the first quarter of 2004 compared to the corresponding period in the prior year due to higher raw material costs, primarily ethylene.

Liquidity and Capital Resources

The Company has historically financed its operations primarily through cash generated from its operations and cash distributions from Equistar, as well as debt financings. In 2003, the Company financed its foreign operations through cash generated from those foreign operations and its domestic operations through cash generated from domestic operations and cash from various sources of external financing. Cash generated from operations is to a large extent dependent on economic, financial, competitive and other factors affecting the Company’s businesses. The amount of cash distributions received from Equistar is affected by Equistar’s results of operations and current and expected future cash flow requirements. The Company has not received any cash distributions from Equistar since 2000 and it is unlikely the Company will receive any cash distributions from Equistar in 2004.

Cash provided by operating activities for the quarter ended March 31, 2004 was $38 million compared to $14 million of cash used in the quarter ended March 31, 2003. The $52 million increase in cash provided by operating activities was primarily due to favorable movements in trade working capital (defined as trade accounts receivable, inventory and trade accounts payable) in the first quarter of 2004 compared to unfavorable movements in the same period of the prior year ($53 million) and movements in accrued expenses and other liabilities in the first quarter of 2004 that were favorable to a greater extent than the first quarter of 2003 ($23 million), partially offset by lower operating income before depreciation and amortization ($19 million) and various other net unfavorable changes ($5 million).

Cash used in investing activities for capital expenditures in the quarter ended March 31, 2004 was $10 million compared to $8 million used for capital expenditures in the first quarter of 2003. The low level of capital spending in the first quarter of both 2004 and 2003 reflects the Company’s continued focus on optimization of its asset base. Capital spending for 2004 is expected to be approximately $60 million. The Company expects to finance its planned capital spending using cash generated from operations and through availability under its Credit Agreement, if necessary.

Cash used in financing activities was $46 million in the first quarter of 2004 compared to $20 million of cash provided by financing activities in the first quarter of 2003. Financing activities in the first quarter of 2004 included $54 million of net repayments of debt, while the first quarter of 2003 included $30 million of net debt proceeds. In the first quarter of 2004, the Company repatriated cash of approximately $107 million from Australia and Europe to the US. This cash was used to reduce outstanding borrowings under the Company’s Credit Agreement and for general corporate purposes. Dividends paid to shareholders totaled $9 million for the first quarter of 2003 and no dividends were paid in the first quarter of 2004. In July 2003, the Company announced the suspension of the payment of dividends on its Common Stock, as more fully described in “Cost Reduction Program; Suspension of Dividend” above.

The maturities of the Company’s long-term debt through 2009 and thereafter are as follows:


	April 1 - December 31, 2004		2005		2006		2007		2008		2009		Thereafter		Total at March 31, 2004			Total at December 31, 2003
	(Millions)
Revolving loans	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—		$	52
7.00% Senior Notes		—		—		500		—		—		—		—		500			500
7.625% Senior Debentures		—		—		—		—		—		—		250		250			250
9.25% Senior Notes		—		—		—		—		475		—		—		475			475
4.00% Convertible Senior Debentures		—		—		—		—		—		—		150		150			150
Other long-term debt		4		5		5		2		1		1		3		21			23

Maturities of long-term debt	$	4	$	5	$	505	$	2	$	476	$	1	$	403		1,396			1,450

Non-cash components of long-term debt																18			17

Total debt																1,414			1,467
Less: current maturities of long-term debt																(5	)		(6	)

Total long-term debt															$	1,409		$	1,461

On November 25, 2003, the Company received approximately $125 million in gross proceeds and, on December 2, 2003, received an additional $25 million in gross proceeds from the sale by Millennium Chemicals Inc. (“Millennium Chemicals”) of $150 million aggregate principal amount of the 4.00% Convertible Senior Debentures, which are guaranteed by Millennium America Inc. (“Millennium America”), a wholly-owned indirect subsidiary of Millennium Chemicals. The gross proceeds of the sale were used to repay all of the $47 million of outstanding borrowings at that time under the term loan portion (the “Term Loan”) of the Company’s five-year credit agreement expiring June 18, 2006 (the “Credit Agreement”) and $103 million of outstanding borrowings under the revolving loan portion (the “Revolving Loans”) of its Credit Agreement, which currently has a maximum availability of $150 million. The Company used $4 million of cash to pay the fees relating to the sale of the 4.00% Convertible Senior Debentures.

On April 25, 2003, the Company received approximately $107 million in net proceeds ($109 million in gross proceeds) from the issuance and sale by Millennium America of $100 million additional principal amount at maturity of its 9.25% Senior Notes due June 15, 2008 (the “9.25% Senior Notes”), which are guaranteed by Millennium Chemicals. The net proceeds were used to repay all of the $85 million of outstanding borrowings at that time under the Revolving Loans and for general corporate purposes. Millennium Chemicals and Millennium America guarantee the obligations under the Credit Agreement. Under the terms of this issuance and sale, Millennium America and Millennium Chemicals entered into an exchange and registration rights agreement with the initial purchasers of the $100 million additional principal amount of these 9.25% Senior Notes. Pursuant to this agreement, each of Millennium America and Millennium Chemicals agreed to: (1) file with the Securities and Exchange Commission on or before July 24, 2003 a registration statement relating to a registered exchange offer for the notes, and (2) use its reasonable efforts to cause this exchange offer registration statement to be declared effective under the Securities Act on or before October 22, 2003. On June 13, 2003, Millennium America and Millennium Chemicals, as guarantor, initially filed a registration statement with the Securities and Exchange Commission, and on December 15, 2003, filed an amended registration statement. However, as of March 31, 2004, the exchange offer registration statement had not yet been declared effective. As a result, since October 22, 2003, Millennium America has been obligated to pay additional interest at the annualized rate of approximately 1.00% to each holder of the $100 million additional amount of notes. This additional interest will be paid until such time as the registration statement becomes effective.

The Company depends on its Credit Agreement as its primary source of liquidity for its operations and working capital needs. At April 30, 2004, the Company had $21 million of outstanding undrawn standby letters of credit and no outstanding borrowings under the Revolving Loans and, accordingly, had $129 million of unused availability under such facility. At that date, in addition to letters of credit outstanding under the Credit Agreement, the Company also had outstanding undrawn standby letters of credit and bank guarantees under other arrangements of $6 million. The

Company had unused availability under short-term uncommitted lines of credit, other than the Credit Agreement, of $42 million at April 30, 2004.

The Credit Agreement contains various restrictive covenants and requires that the Company meet certain financial performance criteria. Compliance with these covenants is monitored frequently in order to assess the likelihood of continued compliance. As a result of the restatement of its prior financial statements as discussed above, the Company obtained waivers on July 29, 2004, and February 2, 2005, under the Credit Agreement relating to certain representations under the Credit Agreement regarding such prior financial statements. The Company was in compliance with all covenants under the Credit Agreement in effect at March 31, 2004.

The financial covenants in the Credit Agreement, prior to the amendment consummated in the fourth quarter of 2003, which is described below, included a Leverage Ratio and an Interest Coverage Ratio. The Leverage Ratio is the ratio of Total Indebtedness to cumulative EBITDA for the prior four fiscal quarters, each as defined in the Credit Agreement prior to the amendment in the fourth quarter of 2003. The Interest Coverage Ratio is the ratio of cumulative EBITDA for the prior four fiscal quarters to Net Interest Expense, for the same period, each as defined in the Credit Agreement prior to the amendment in the fourth quarter of 2003. To permit the Company to be in compliance, these covenants were also amended in the fourth quarter of 2001, in the second quarter of 2002, and in the second quarter of 2003. The amendment in the second quarter of 2002 was conditioned upon the consummation of an offering in June 2002 of $100 million additional principal amount of the 9.25% Senior Notes and using such proceeds for the repayment of all of the $35 million of outstanding borrowings at that time under the Revolving Loans and to repay $65 million outstanding under the Term Loans. The amendment in the second quarter of 2003 was not conditioned on the sale of $100 million additional principal amount of the 9.25% Senior Notes in April 2003. The amendment in the fourth quarter of 2003 was conditioned on the Company obtaining at least $110 million of long-term financing in the capital markets, which the Company satisfied by the sale by Millennium Chemicals of the 4.00% Convertible Senior Debentures. The amendment in the fourth quarter of 2003 amended, among other things, the maximum availability under the Credit Agreement from $175 million to $150 million, the performance criteria for the Interest Coverage Ratio, the definition of EBITDA, and replaced the Leverage Ratio with a Senior Secured Leverage Ratio. Under the financial covenants now in effect, the Company is required to maintain a Senior Secured Leverage Ratio, defined as the ratio of Senior Secured Indebtedness, as defined, to cumulative EBITDA for the prior four fiscal quarters, each as defined, of no more than 1.25 to 1.00 for each of the remaining quarters of 2004 and 1.00 to 1.00 for the first quarter of 2005 and thereafter, and an Interest Coverage Ratio, defined as the ratio of cumulative EBITDA for the prior four fiscal quarters to Net Interest Expense, for the same period, each as defined, of no less than 1.35 to 1.00 for the first and second quarters of 2004; 1.40 to 1.00 for the third quarter of 2004; 1.50 to 1.00 for the fourth quarter of 2004; and 1.75 to 1.00 for the first quarter of 2005 and thereafter. The covenants in the Credit Agreement also limit, among other things, the ability of the Company and/or certain subsidiaries of the Company to: (i) incur debt and issue preferred stock; (ii) create liens; (iii) engage in sale/leaseback transactions; (iv) declare or pay dividends on, or purchase, the Company’s stock; (v) make restricted payments; (vi) engage in transactions with affiliates; (vii) sell assets; (viii) engage in mergers or acquisitions; (ix) engage in domestic accounts receivable securitization transactions; and (x) enter into restrictive agreements. In the event the Company sells certain assets as specified in the Credit Agreement, and the Leverage Ratio is equal to or greater than 3.75 to 1.00, the outstanding Revolving Loans must be prepaid with a portion of the Net Cash Proceeds, as defined, of such sale. In addition, the maximum availability under the Credit Agreement will be decreased by 50% of the aggregate Net Cash Proceeds received from such asset sales in excess of $100 million from November 18, 2003, the effective date of the fourth quarter 2003 amendment. Any sale involving Equistar or certain inventory or accounts receivable will reduce the maximum availability under the Credit Agreement by 100% of such Net Cash Proceeds received. The obligations under the Credit Agreement are collateralized by: (1) a pledge of 100% of the stock of the Company’s existing and future domestic subsidiaries and 65% of the stock of certain of the Company’s existing and future foreign subsidiaries, in both cases other than subsidiaries that hold immaterial assets (as defined in the Credit Agreement); (2) all the equity interests held by the Company’s subsidiaries in Equistar and the La Porte Methanol Company (which pledges are limited to the right to receive distributions made by Equistar and the La Porte Methanol Company, respectively); and (3) all present and future accounts receivable, intercompany indebtedness and inventory of the Company’s domestic subsidiaries, other than subsidiaries that hold immaterial assets. As a result of the announced stock-for-stock business combination with Lyondell, the Company will have to obtain amendments or waivers of certain provisions of its Credit Agreement prior to the closing of the proposed transaction. At a minimum, the Company expects that it will have to obtain a waiver of Section 6.05 of the Credit Agreement, which relates to the covenant that the Company will not consolidate with or merge into any other person or sell or otherwise dispose of certain assets, as defined, and Section 7(m), which relates to a Change in Control triggering an Event of Default, each as defined.

Millennium America also has outstanding $500 million aggregate principal amount of 7.00% Senior Notes due November 15, 2006 (the “7.00% Senior Notes”) and $250 million aggregate principal amount of 7.625% Senior

Debentures due November 15, 2026 (the “7.625% Senior Debentures” and, together with the 7.00% Senior Notes and the 9.25% Senior Notes the “Senior Notes”), that are fully and unconditionally guaranteed by Millennium Chemicals. The indenture under which the 7.00% Senior Notes and 7.625% Senior Debentures were issued contains certain covenants that limit, among other things: (i) the ability of Millennium America and its Restricted Subsidiaries (as defined) to grant liens or enter into sale/leaseback transactions; (ii) the ability of the Restricted Subsidiaries to incur additional indebtedness; and (iii) the ability of Millennium America and Millennium Chemicals to merge, consolidate or transfer substantially all of their respective assets. This indenture allows Millennium America and its Restricted Subsidiaries, as defined, to grant security on loans of up to 15% of Consolidated Net Tangible Assets (“CNTA”), as defined, of Millennium America and its consolidated subsidiaries. Accordingly, based upon CNTA and secured borrowing levels at March 31, 2004, any reduction in CNTA below approximately $1 billion would decrease the Company’s availability under the Revolving Loans by 15% of any such reduction. CNTA was approximately $2 billion at March 31, 2004. The 7.00% Senior Notes and the 7.625% Senior Debentures can be accelerated by the holders thereof if any other debt in excess of $20 million is in default and is accelerated.

•

on or after November 15, 2018, at any time after the closing price of the Company’s Common Stock on any date is greater than 125% of the then current conversion price;

•

if the debentures are called for redemption;

•

The debentures are redeemable at the Company’s option beginning November 15, 2010 at a redemption price equal to 100% of their principal amount, plus accrued interest, if any. On November 15 in each of 2010, 2013 and 2018, holders of debentures will have the right to require the Company to repurchase all or some of the debentures they own at a purchase price equal to 100% of their principal amount, plus accrued interest, if any. The Company may choose to pay the purchase price in cash or shares of the Company’s Common Stock or any combination thereof. In the event of a conversion request upon a credit ratings event as described above, after June 18, 2006, the Company has the right to deliver, in lieu of shares of Common Stock, cash or a combination of cash and shares of Common Stock. Holders of the debentures will also have the right to require the Company to repurchase all or some of the debentures they own at a cash purchase price equal to 100% of their principal amount, plus accrued interest, if any, upon the occurrence of certain events constituting a Fundamental Change, as defined in the indenture. This indenture also limits the Company’s ability to consolidate with or merge with or into any other person, or sell, convey, transfer or lease properties and assets substantially as an entirety to another person, except under certain circumstances. The consummation of the announced stock-for-stock business combination with Lyondell is not expected to be considered a Fundamental Change, as defined in the indenture. However, the Company does expect to be required to execute with the trustee a supplemental indenture providing that each debenture shall be convertible into Lyondell’s common stock at a conversion ratio as adjusted in accordance with the Agreement of Merger between the Company and Lyondell.

The Company’s focus in 2004 is to sustain the benefits of cost reduction efforts achieved to date, achieve further benefits from cost reduction actions announced in the third quarter of 2003, and manage working capital and capital spending to levels deemed reasonable given the current state of business performance. In the first quarter of 2004, the Company repatriated approximately $107 million from its Australian and European businesses to the US. This cash was used primarily to reduce outstanding borrowings under the Company’s Credit Agreement and for general corporate purposes. The Company believes these efforts, along with the borrowing availability under the Credit Agreement, and considering the suspension of the payment of dividends on the Company’s Common Stock announced in the third quarter of 2003, will be sufficient to fund the Company’s cash requirements until 2006. At that time, the Company must repay or refinance the 7% Senior Notes and renegotiate or refinance the Credit Agreement.

Critical Accounting Estimates

The preparation of the Company’s financial statements requires management to apply accounting principles generally accepted in the United States of America to the Company’s specific circumstances and make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

There have been no revisions to the critical accounting estimates as originally filed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2003, and as amended by Amendment No. 5 on Form 10-K/A filed with the Securities and Exchange Commission on February 14, 2005.

Recent Accounting Developments

See Note 4 to the unaudited Consolidated Financial Statements included in this Amendment No. 4 for discussion of recent accounting developments.

Item 4.

Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the Company’s filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

On November 30, 2004, the Company became a wholly owned subsidiary of Lyondell. As a result of the acquisition of the Company by Lyondell, the Company’s Board of Directors and executive management were replaced with a new Board of Directors and a new executive management team. Lyondell and the Company are in the process of integrating the Company’s internal control over financial reporting into the Lyondell control processes. During the integration process, key Company controls that have been in place historically are being maintained, while supplementing such controls with key elements of the Lyondell control framework.

Material Weakness in Controls over Accounting for Deferred Income Taxes

As a result of tax integration activities that began in the second quarter of 2004 with respect to the acquisition of the Company by Lyondell, the Company determined at the beginning of July 2004 that it had made errors in the computation of its tax basis in Equistar, which in turn had been used to compute the Company’s deferred income taxes. In response to the determination that errors had been made, the Company performed an analysis and re-computation of the Company’s tax basis in Equistar. In late July 2004, the Company completed the analysis and re-computation necessary to verify and quantify the errors and prepare the August 2004 Restatement to correct the errors, which August 2004 Restatement was reflected in Amendment No. 2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2003; Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2004 (“Amendment No. 1”); and the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2004, all of which were filed with the SEC on August 9, 2004.

The August 2004 Restatement of prior periods’ financial statements that resulted from the analysis and re-computation discussed above decreased the Company’s liability for deferred income taxes and shareholders’ deficit at June 30, 2004, March 31, 2004, and December 31, 2003 and 2002 by $15 million. The August 2004 Restatement similarly decreased liabilities for deferred income taxes and increased shareholders’ equity at December 31, 2001 and 2000 by $15 million. The August 2004 Restatement did not affect the Company’s cash flow or operating income in any period.

The errors corrected in the August 2004 Restatement were the result of (1) an incorrect computation by the Company in 1998 of the Company’s original tax basis in the net assets it contributed to Equistar upon the joint venture’s formation in December 1997 and (2) incorrect computations by the Company for 1998 and 1999 of changes in the amount of such tax basis. The Company also discovered a de minimis error made in 2001. The Company believes that the errors were attributable to a material weakness in internal control over financial reporting relating to the computation by the Company of deferred income taxes for the Company’s investment in Equistar (the “First Material Weakness”).

The First Material Weakness consisted of (1) inadequate review and verification by the Company in 1998 of tax basis data relating to net assets contributed by the Company to Equistar in December 1997 and (2) incorrect interpretation by the Company of Equistar tax return information provided by the “tax matters partner” of Equistar and used by the Company to compute changes in its tax basis in Equistar for 1998 and 1999. Under Equistar’s partnership agreement, Lyondell serves as the tax matters partner and, as such, prepares and files Equistar’s tax returns.

In order to remediate the First Material Weakness, in the third quarter of 2004, the Company documented the procedures that were used to analyze and re-compute the Company’s tax basis in Equistar during July 2004 for implementation with respect to the third quarter of 2004 and subsequent reporting periods. These procedures documented in the third quarter of 2004 included (1) the detailed review by the Company’s Director-Tax and its Vice President-Tax of estimates of tax return data provided quarterly by Equistar’s tax matters partner, (2) followed by discussions of the results of such review with the tax matters partner to confirm the correctness of the Company’s interpretation of the estimated tax return data provided by the tax matters partner and (3) thereafter, review of the results of these procedures by the Company’s Corporate Controller and Chief Financial Officer (the Company’s Principal Accounting Officer).

After the November 30, 2004 acquisition of the Company by Lyondell, the new management team reviewed the Company’s deferred tax accounts in conjunction with the preparation of the financial statements of Lyondell and the Company as of December 31, 2004 utilizing the existing Lyondell internal control over financial reporting related to deferred income taxes. The Lyondell tax controls and procedures are being implemented at the Company in the fourth quarter of 2004 and the first quarter of 2005 to complete the remediation of the First Material Weakness. These Lyondell controls and procedures include (1) detailed review by the Lyondell Director – Worldwide Tax Reporting of the tax and book bases associated with the Company’s and Lyondell’s investments in Lyondell’s wholly-owned indirect subsidiary, Equistar, and the related deferred tax assets and liabilities, using both information available to Lyondell as the Equistar tax matters partner and information previously available to the Company; and (2) review and concurrence with that detailed review by Lyondell’s Vice President – Tax, Lyondell’s Senior Tax Counsel, and the Company’s Vice President – Tax, as well as the Company’s Vice President and Controller (the Company’s Principal Accounting Officer, who is also the Lyondell Vice President and Controller and Principal Accounting Officer) and the Lyondell Assistant Controller. These procedures were utilized by the new Company management to confirm the deferred taxes related to the Company’s investment in Equistar reflected in the financial statements included in this Amendment No. 4; however, the First Material Weakness will not be considered remediated until these procedures operate for a period of time, are tested and it is concluded that such procedures are operating effectively at the reasonable assurance level.

Material Weakness in Controls over Accounting for Contingencies

Also subsequent to the November 30, 2004 acquisition date, the new Company management re-examined the Company’s environmental remediation liabilities in conjunction with the preparation of the financial statements of Lyondell and the Company as of and for the year ended December 31, 2004, following procedures that are part of the Lyondell internal control over financial reporting. In late January of 2005, the Company concluded, with the concurrence of the Company’s Board of Directors, that the Company’s financial statements for the three-year period ending December 31, 2003 and the first three quarters of 2004 should no longer be relied upon because of errors in such financial statements. Accordingly, in February 2005, the Company restated its financial statements for those periods to recognize an increase of $52 million in its recorded liabilities for environmental remediation as of September 30, 2004 to record additional amounts for estimated future environmental remediation spending that were not recorded previously. This increase in environmental remediation liabilities results, as of September 30, 2004, in a decrease in deferred tax liabilities of $17 million, and an increase in accumulated deficit of $35 million, of which $18 million relates to years prior to 1999. The February 2005 Restatement is reflected in Amendment No. 5 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2003; this Amendment No. 4; Amendment No. 4 to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2004; and Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2004.

The errors corrected in the February 2005 Restatement were the result of failure to increase the probable liabilities for future remediation spending related to past environmental contamination when the reasonably estimable amounts of such probable future spending increased. The Company believes that the errors were attributable to a material weakness in internal control over financial reporting relating to the recording by the Company of the probable liabilities related to

contingencies, including environmental remediation obligations (the “Second Material Weakness”). The Second Material Weakness consisted of (1) inadequate procedures to verify the appropriateness of period-end balances of recorded liabilities reflecting the Company’s best estimate of probable future spending associated with contingent liabilities and (2) ineffective communication among the corporate functions with knowledge and accountability relating to environmental remediation, legal contingencies, accounting, and disclosure.

In order to remediate the Second Material Weakness, the Company documented, in the first quarter of 2005, the procedures that were used to reevaluate the Company’ environmental remediation liabilities, which include application of Lyondell control processes to the Company. The Company utilized these documented procedures in preparing the financial statements contained in this Amendment No. 4. These Lyondell controls and procedures include:

•

relating to liability for environmental remediation:

detailed review by the Lyondell General Manager HS&E, the Lyondell Senior Corporate Counsel – Environmental, the Lyondell Manager – Environmental Affairs and the Lyondell Manager – Environmental Issues of the current status of previously existing, new and potential remediation projects, including spending estimates,

detailed review and discussion of each project and related estimates with the above parties and the Company’s Vice President and Controller (who is also the Lyondell Vice President and Controller), the Lyondell Senior Manager of Accounting Policy, and the Lyondell Assistant Controller, and

detailed assessment of the appropriate accounting for those estimates by the Company’s Vice President and Controller, the Lyondell Senior Manager of Accounting Policy, and the Lyondell Assistant Controller; and

•

relating to legal contingencies:

detailed review and assessment of all existing and known potential litigation by the Lyondell Associate General Counsel-Litigation, the Lyondell Corporate and Securities Counsel, and the Lyondell Litigation department,

detailed review and discussion of those matters that may have accounting or financial disclosure impacts by the Lyondell Associate General Counsel-Litigation, the Lyondell Corporate and Securities Counsel and the Lyondell Assistant Controller, and

detailed assessment of the appropriate accounting and financial disclosure for legal contingencies by the Company’s Vice President and Controller, the Lyondell Senior Manager of Accounting Policy and the Lyondell Assistant Controller.

The Company intends to continue to use these procedures in preparing its financial statements for subsequent reporting periods; however, the Second Material Weakness will not be considered remediated until these procedures operate for a period of time, are tested and it is concluded that such procedures are operating effectively at the reasonable assurance level. In addition, as a result of the acquisition of the Company by Lyondell and the resultant change in the executive management team, additional procedures were followed during the fourth quarter of 2004 and the first quarter of 2005 to confirm the financial statements included in this Amendment No. 4, including inquiry of previous management, discussion with outside counsel and discussion with outside consulting engineers.

Evaluation of Disclosure Controls and Procedures

Before filing Amendment No. 1, the Company completed an evaluation under the supervision and with the participation of the Company’s then-existing management team, including the Company’s principal executive officer and principal financial officer at that time (“Former Management”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of March 31, 2004. Based on this evaluation, the Former Management of the Company concluded that, solely as a result of the First Material Weakness referred to above, the Company’s disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2004. In addition, in connection with this Amendment No. 4, the Company completed an evaluation under the supervision and with the participation of the Company’s current management team, including the Company’s current

principal executive officer and current principal financial officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of March 31, 2004, after taking into consideration the prior evaluation. Based on the evaluation, the current principal executive officer and current principal financial officer of the Company concluded that the Company’s disclosure controls and procedures also were not effective at the reasonable assurance level as of March 31, 2004 due to the Second Material Weakness described above. However, as a result of the new management team’s most recent reevaluation of liabilities for contingencies, as well as its detailed review of deferred tax liabilities, both discussed above, and its utilization of the documented procedures in preparing the financial statements contained in this Amendment No. 4 as described above, management believes that the financial statements included in this Amendment No. 4 present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the periods presented.

There were no changes in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter covered by this Amendment No. 4 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. However, as discussed above, after the November 30, 2004 acquisition by Lyondell, the new management team reviewed the deferred tax computations and analysis and the computation and analysis of liabilities for contingencies, including liabilities for environmental remediation, for the fourth quarter 2004 and for the year ended December 31, 2004 utilizing existing Lyondell controls and procedures. These Lyondell controls and procedures continue to be implemented at the Company in the first quarter of 2005 to complete the remediation of the First Material Weakness and the Second Material Weakness.

As a result of Section 404 of the Sarbanes-Oxley Act of 2002 and the rules issued thereunder (the “Section 404 Requirements”), the Company will be required to include in its Annual Report on Form 10-K for the year ending December 31, 2005 a report on management’s assessment of the effectiveness of the Company’s internal control over financial reporting. As part of the process of preparing for compliance with the Section 404 Requirements, the Company initiated in 2003 a review of its internal control over financial reporting. This review now is being conducted under the direction of the Company’s new management team. As a result, the new management team has made improvements, as described above, to the Company’s internal control through the date of the filing of this Amendment No. 4 as part of this review. The Company anticipates that improvements will continue to be made as part of the ongoing review.

PART II. OTHER INFORMATION

Item 6.

Exhibits and Reports on Form 8-K


(a)	Exhibits –

	31.1	Certificate of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	31.2	Certificate of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	32.1	Certificate of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished, not filed, in accordance with Item 601(b)(32)(ii) of Regulation S-K, 17 CFR 229.601(b)(32)(ii)).*

	32.2	Certificate of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished, not filed, in accordance with Item 601(b)(32)(ii) of Regulation S-K, 17 CFR 229.601(b)(32)(ii)).*

	99.1	Information Relevant to Forward-Looking Statements.**

*	Filed or furnished herewith.

**	Incorporated by reference to Exhibit 99.1 to the original Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 and filed on May 14, 2004.

(b)	Reports on Form 8-K.

Current Reports on Form 8-K dated March 29, 2004 and May 5, 2004 were filed or furnished during the quarter ended March 31, 2004 and through May 14, 2004, the date the original Quarterly Report on Form 10-Q was filed with the Securities and Exchange Commission. Such Current Reports either filed or furnished information to the Securities and Exchange Commission.

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		MILLENNIUM CHEMICALS INC.

Date: February 14, 2005	By:	/s/ CHARLES L. HALL
		Charles L. Hall
		Vice President and Controller (Duly Authorized Officer and Principal Accounting Officer)

Exhibit Index


Exhibit Number		Description of Document

31.1		Certificate of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certificate of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certificate of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished, not filed, in accordance with Item 601(b)(32)(ii) of Regulation S-K, 17 CFR 229.601(b)(32)(ii)).

32.2		Certificate of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished, not filed, in accordance with Item 601(b)(32)(ii) of Regulation S-K, 17 CFR 229.601(b)(32)(ii)).